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ABSTRACT OF CAPSTONE 
ADDRESSING BARRIERS TO HEPATITIS C TREATMENT 
INITIATION IN KENTUCKY CLINIC 
Introduction. Hepatitis C virus (HCV) is the most prevalent blood borne 
infection in the United States and its chronic infection has a high burden on the 
American healthcare system. Since 2014, the all-oral Directly Acting Antiviral 
(DAA)-based therapy has been established as the standardized curative 
treatment for HCV with unprecedented high effectiveness and tolerability. 
Nevertheless, there is a significant gap between the promise from DAAs benefits 
and the treatment initiation rates in the United States and Kentucky.  
Objectives. The goal of this study is to improve the access to the all-oral 
DAA-based treatment among HCV patients seeking outpatient treatment services 
at the Kentucky Clinic. 
Methods. This study was conducted from October to December 2016 in 
the specialized HCV outpatient clinic at the Kentucky Clinic in Fayette County, 
Lexington, Kentucky. The study utilized a mixed methods approach to address 
the barriers for initiating HCV treatment. The qualitative analysis explored the 
current model of care applied to the patients seeking HCV treatment, its tools 
included: field observations, semi-structured in-depth interviews with healthcare 
personnel providing administrative and clinical services to HCV patients, and 
review of relevant administrative forms. The quantitative analysis followed a 
retrospective cohort design including all chronic HCV patients who had their first 
visit to the Kentucky Clinic between July 1, 2014 and June 30, 2015. The 
observation time for this cohort was calculated from the first visit until treatment 
initiation or the last day of observation November 30, 2016. To assess the 
predictors for treatment initiation, we assessed the sociodemographic, clinical, 
and behavioral variables of the study cohort. Quantitative analysis included 
descriptive analysis of the patients’ explanatory variables comparing those who 
initiated treatment to those who did not followed by time to treatment analysis for: 
assessing the cumulative incidence of treatment initiation, constructing Kaplan–
Meier time to treatment curves estimating the proportion of patients who initiated 
treatment at different time points comparing each explanatory variable levels, 
and identifying the predictive independent variables for treatment initiation over 
time using Cox Proportional Hazards Regression analysis. 
Results. Multiple interrelated difficulties in accessing the DAAs treatment 
were found of relevance to the current model of care and patients’ 
characteristics. The treatment initiation journey is long and hindered by 
complicated stepwise administrative and clinical procedures. Lack of proper 
communication between the referring facility, the scheduling center, and the HCV 
clinic is obvious. Lack of awareness among the patients and their referring 
provider concerning the treatment initiation procedures add to the difficulty in 
communication. In general, the HCV treatment services are broken and not 
properly connected with other services needed by HCV patients. The 
administrative and clinical procedures are centered around the PA requirements 
and Medicaid applied restrictive criteria favoring advanced liver disease patients 
which requires a clinical proof difficult to achieve in border line cases between 
the mild and advanced liver disease stages. The quantitative results showed that 
a total of 880 HCV patients visited the HCV clinic at the Kentucky Clinic between 
July 1, 2014 and June 30, 2015. Only 195 (22.16%) patients initiated the DAAs 
treatment during the observation period. Time to treatment initiation results are 
consistent with the long waiting time found in the model of care results. The 
average number of days to initiate treatment was 263.57 days. Univariate 
analysis using Kaplan-Meier time to treatment initiation estimates showed 
significant earlier treatment among males, African Americans, patients who 
followed-up at least once, and patients without a history of substance abuse. The 
disproportionate treatment initiation achievement among the patients born before 
1965 was inconsistent under Medicaid coverage and with mild liver disease; 
patients showed significantly later treatment initiation at different points of time. 
Bivariate analysis of insurance and liver disease condition showed that Medicaid 
patients with mild liver disease had the lowest chance for treatment initiation at 
different time points compared to other groups. The cox model significance 
results confirmed the previous results on age group, insurance type, and liver 
disease condition. Medicare baby boomers have almost double and more than 
quadruple the likelihood of Medicaid baby boomers to initiate treatment at 
advanced and mild liver disease stages respectively. This likelihood jumps to five 
and thirteen times respectively on comparing patients born after 1965 with the 
same characteristics. Likewise, Medicaid baby boomers have less than half the 
likelihood of private and other insurance patients to initiate treatment at either 
disease stages. In parallel, the Medicaid patients born after 1965 have nearly 
quarter the likelihood of private and other insurance patients to initiate treatment 
at either disease stage. The only significant likelihood difference between 
Medicare and private and other types of insurance was found among mild liver 
disease patients born after 1965 where the former group are three times as likely 
as the latter group to initiate treatment. 
Conclusion. Access to HCV treatment in the Kentucky Clinic is hindered 
by a variety of barriers revolving mainly around the model of care, which is 
greatly influenced by the insurance system. Structural adjustment for the current 
model of care and prioritizing the disproportionately affected groups of patients 
by HCV infection is urgently needed. This study proposes a patient centered 
comprehensive model of care fostering a patient navigation system providing: 
early linkage and continuity of care, patient education based on a baseline needs 
assessment, and awareness for the referring provider about the treatment 
process. In addition, administrative support is mandatory to speed up the process 
utilizing data linkage with other healthcare facilities and a special prior 
authorization support system. Integration of HCV services with other services 
including primary care, substance abuse management, and other social services. 
Prioritization should consider Medicaid young patients living in southeast 
Kentucky with mild liver disease and practicing injection drug use.  HCV 
treatment task shifting to primary providers in the southeastern Appalachian 
counties is key solution on the long term.   
KEYWORDS: hepatitis C, access, barriers, treatment, directly acting 
antivirals, initiation, prior authorization, Kentucky. 
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CHAPTER 1 
INTRODUCTION 
I- Background  
About 3.6 million Americans carry hepatitis C (HCV) antibodies and 2.7 
million are chronically infected. This alarming prevalence renders HCV the most 
prevalent blood borne infection in the United States (US) (Denniston et al., 2014). 
Moreover, there is a steady increase in acute HCV infections across the nation 
adding to the problem of its high prevalence (Centers for Disease Control and 
Prevention, 2016).  
Chronic HCV infection is the leading cause of chronic liver disease, 
hepatocellular carcinoma (HCC) i.e. liver cancer, and liver transplantation (LT) in 
the US (Ditah et al., 2014). HCV related mortality is continuously increasing with 
an average annual increase 6.2% (Ly, Hughes, Jiles, & Holmberg, 2016). The 
burden of HCV on the American healthcare system is a major challenge. Each 
year HCV patients make more than 2.3 million outpatient visits, 73,000 visits to 
emergency departments, and 475,000 hospitalizations (Galbraith et al., 2014). 
This burden is associated with corresponding healthcare costs estimated at $6.5 
billion in 2011 (Shah, Younossi, & Opsha, 2015). 
Since 2014, the all-oral Directly Acting Antiviral (DAA)-based therapy has 
been established as the standardized curative treatment for HCV with 
unprecedented high effectiveness and tolerability. This breakthrough therapy 
created a promise for the elimination of HCV (American Association for The 
Study of Liver Diseases, 2016). Clinical outcomes from DAAs are maximized 
when a cure is achieved; however, all HCV patients gain liver function 
improvement and a favorable disease prognosis (Rodriguez & Reynolds, 2016; 
Z. M. Younossi, Birerdinc, & Henry, 2016).  
National spending on DAAs showed a tremendous increase since their 
approval by the US Food and Drug Administration (FDA) in late 2013 (IMS 
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Institute for Healthcare Informatics, 2016). Although DAAs are costly, their 
effectiveness outweighs their costs (Z. M. Younossi, Park, Dieterich, et al., 2016). 
Guidance from specialty organizations calls for expansion of HCV detection and 
early treatment with DAAs (DeSalvo, Scott, Wolitski, & Dan, 2017). 
II- Problem Statement 
Unfortunately, the promise of DAAs for HCV elimination is hindered by 
many challenging barriers. The treatment cascade of HCV from screening to 
treatment initiation reveals insufficient response from the American health 
system. The most challenging step in the treatment cascade begins from 
confirmation of diagnosis and declaring eligibility for treatment until the initiation 
of the all-oral DAA-based therapy (Yehia, Schranz, Umscheid, & Lo Re, 2014).  
At institutional levels, there is a large variability in treatment initiation rates  
since the interferon (IFN)-based therapy era, suggesting that barriers are diverse 
and context specific (Denniston et al., 2014; Ditah et al., 2015; Ford et al., 2017; 
Holmberg, Spradling, Moorman, & Denniston, 2013; Maier, Ross, Chartier, 
Belperio, & Backus, 2016; Noska, Belperio, Loomis, O’Toole, & Backus, 2017; 
Stepanova & Younossi, 2015; Vutien, Hoang, Brooks, Nguyen, & Nguyen, 2016; 
Z. Younossi, Stepanova, Afendy, Lam, & Mishra, 2013). Additionally, the 
characteristics of HCV patients and their comparative treatment initiation rates 
have been found to be inconsistent across different contexts and states (Bourgi, 
Brar, & Baker-Genaw, 2016; Centers for Disease Control and Prevention, 2016; 
Denniston et al., 2014; Ford et al., 2017; Kanwal et al., 2016) 
In Kentucky, the burden of HCV and the characteristics of patients are 
alarming. This Midwestern state is ranked among the highest states in HCV 
prevalence and incidence (National Center for HIV/AIDS, Viral Hepatitis, STD, 
2015). In particular, the southeastern counties of Kentucky, located in the 
Appalachian Mountains, possess the highest HCV infection rates due to the 
predominant use of injection drugs (IDU) (Havens et al., 2013).  Moreover, the 
Kentucky Medicaid program which covers the majority of HCV patients applies 
very restrictive criteria for DAA-based treatment approval that challenge the most 
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needy individuals residing in southeast Kentucky who have  limited geographical 
access to HCV treatment specialists (Barua et al., 2015).  
The Kentucky Clinic, the setting of this study, reported a significant 
increase in utilization of specialized services by HCV patients between 2010 and 
2015. The profile of these patients revealed that they are predominantly: males, 
Caucasians, born after 1965, under Medicaid coverage, and reside in rural 
southeastern Kentucky (Abdelwadoud, Racho, & Rosenau, 2017).  
To this end, there appears to be a significant gap between the promise 
from DAAs benefits and treatment initiation rates. The gap in knowledge and 
practice for improving HCV treatment initiation rates pertains to influential factors 
that vary among different contexts. Each context has its specific demand and 
supply profile; thus, a thorough contextual understanding of the DAAs demand 
and supply in Kentucky is urgently needed.  
III- Study Purpose 
The goal of this study is to improve the access to the all-oral DAA-based 
treatment among HCV patients seeking outpatient treatment services at the 
Kentucky Clinic. To achieve this goal, this study targeted the following objectives: 
1. To describe the administrative and clinical procedures in the Kentucky Clinic 
applied to HCV patients seeking the standardized DAA-based therapy 
beginning from their referral until achieving the required approval for 
treatment initiation. 
2. To outline an administrative and clinical flowchart describing the current 
model of care for HCV patients in the Kentucky Clinic.  
3. To determine the sociodemographic, clinical, and behavioral characteristics of 
HCV patients influencing their initiation of treatment.  
4. To develop a proposed comprehensive model of care aiming at improving 
HCV patients’ access to treatment in the Kentucky Clinic based on the needs 
identified from the current model of care and the patients’ characteristics. 
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IV- Research Question 
The research question of this study is what are the barriers that prevent, 
or make it difficult, the Kentucky Clinic HCV patients from initiating the DAA-
based treatment? 
V- Research Hypotheses 
Since the study investigates both the model of care and patients’ 
characteristics, it assumes two hypotheses: 
For the model of care, the null hypothesis assumes that the current model 
of care perfectly enables the access to DAAs-based treatment and offers no 
obstacles for treatment initiation. 
(H01) = there are no barriers associated with the current model of care for 
DAAs-based treatment initiation in the Kentucky Clinic.  
For the patients’ characteristics, the null hypothesis assumes that there is 
no significant difference in the characteristics of patients who initiate treatment 
and those who do not initiate treatment. 
(H02) = there is no difference between the characteristics of the patients 
who initiate the DAAs-based treatment and those who do not initiate the 
treatment in the Kentucky Clinic.  
VI- Study Limitations 
There are some limitations in interpreting and applying the results of this 
study. First and foremost, the results of this study apply to the Kentucky Clinic 
context as a healthcare facility having a specific model of care, clients, and 
providers.  
While the implications drawn from the results of this study can be valid for 
health services throughout the Commonwealth of Kentucky, it should be noted 
that the specific inferences and proposed model of care indicated in this study 
apply to the Kentucky Clinic in particular. There would be other valid options not 
proposed in the final model that could be apply to other healthcare facilities.  
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Another limitation of the study is that the analysis of patients’ 
characteristics is based on secondary data which could be subject to 
documentation errors. Additionally, since the measures used for the analysis 
were limited by the available data in the patients’ medical records, treatment 
initiation can be influenced and explained by other predictors not included in the 
analysis.  
Finally, given the diversity and complexity of the dimensions of access, 
influencing factors, and determinants; this study was unable to address them in 
their entirety. 
VII- Organization of This Study 
Following this introduction, chapter 2 presents a comprehensive literature 
review directed at understanding the complexity of access to the DAAs-based 
therapy for HCV. It illustrates the background of HCV, then reviews the 
conceptual frameworks proposed in the access to health services literature in 
order to develop a conceptual framework for assessing access to HCV DAA-
based treatment. This framework will guide the study review, methods, results 
and discussion thereafter. The second part of chapter 2 covers the five access 
dimensions: availability, affordability, geographical accessibility, acceptance, and 
accommodation; followed by a description of these dimensions in the 
Commonwealth of Kentucky; and thirdly concludes with a literature review 
summary and a comment on the empirical and theoretical bases of this research.  
In chapter 3, the research methods employed in this research are 
illustrated including: study design, study settings, target population, procedures, 
instrumentation, data analysis strategies, and ethical considerations.  
Chapter 4 presents the study results in two sections: qualitative and 
quantitative analyses, followed by a joint interpretation of these results. Chapter 5 
summarizes the results and assesses them, discusses the implications of the 
study findings, and finally proposes practical recommendations for improving 
access to HCV treatment in the Kentucky Clinic. 
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CHAPTER 2 
LITERATURE REVIEW 
Literature Search Strategy 
This review followed a systematic literature search to understand the key 
concepts and assess the empirical evidence for understanding the factors 
influencing access to the all-oral, IFN-free, DAA therapy for HCV infection in the 
US with particular focus on Kentucky. Comprehensive application of the 
theoretical and empirical knowledge of the health services research discipline 
was followed in this review.  
The search was conducted across the internet databases: Google, 
MEDLINE, Google Scholar, PubMed, and the Cochrane Systematic Review 
Database. The search strategy was designed to include all relevant scientific 
articles; original research; reviews; commentaries; expert opinions; case reports; 
conference proceedings and posters; doctoral and master's degree dissertations; 
websites of research projects; and strategies, action plans, and reports published 
by governmental and non-governmental organizations in the US.  
All identified references were reviewed against the study objectives using 
a process of positive exclusion; first skimming titles and abstracts for relevancy 
followed by reviewing the full text. Further, the reference lists of collected sources 
were reviewed to add other relevant sources to the pool.  
This review inclusion criteria considered only sources addressing HCV 
IFN-free treatment initiation in the US using alternatively combined key terms in 
English: hepatitis C, access, barriers, treatment, directly acting antivirals, 
interferon free, initiation, uptake, insurance, cost, prior authorization, Kentucky, 
and United States. 
Given the exclusive use of standardized IFN-free therapy during the study 
period and the fact that the first-generation of DAAs were added to the previous 
7 
 
IFN-based treatment in 2011, followed by the FDA approval for second-
generation DDAs use without IFN in December 2013 (Ponziani et al., 2017); the 
provisional search included knowledge products published from January 2000 till 
March 2017 to capture all sources relevant to HCV background followed by 
screening sources published from January 2012 to include only those relevant to 
the concurrent influencing factors on accessing the standardized DAA-based 
therapy with special caution in the interpretation of results on combined IFN and 
DAAs treatment regimens. 
Chapter Overview 
The first section of this chapter provides the background of HCV, including 
the virus: discovery, virological characteristics, method of transmission, 
prevention, and natural history. The prevalence and incidence statistics for HCV 
in the US are then considered followed by the morbidity, mortality, and economic 
burdens of HCV in the US.  
The second section explores access models for HCV services. It provides 
a critical review of the different conceptual models of access to health services 
including those specific to chronic diseases and HCV. This analysis concludes 
with a proposed conceptual framework for assessing access to HCV DAA-based 
treatment.  
The third section is structured around the conceptual framework; it is 
organized by the five identified dimensions of access to HCV treatment. The 
influencing factors of these dimensions on HCV DAA treatment in the US are 
discussed in this section. The first part covers the availability dimension; it starts 
with introducing the available diagnostic tools that detect patients in need for 
treatment and then charts the timeline of HCV curative treatment from the 
discovery of the virus to date with special attention to the health benefits of the 
DAAs. A discussion of the providers’ availability and DAAs’ prescription 
requirements then follows. This part continues by examining the treatment 
cascade and initiation rates in the US at national and institutional levels. The 
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following item of this section describes the characteristics of HCV patients in 
different US regions.  
The second part focuses on affordability; it commences with the economic 
benefits of DAAs followed by the national spending on them. Then, this part 
presents the organizational and administrative procedures for the procurement of 
DAAs and their estimated prices. It then presents the distribution of HCV patients 
among different insurance coverages followed by the approval criteria set by 
these insurers. Given its special approval criteria and broad coverage, this part 
provides some details on Medicaid, the federally funded and state managed 
subsidized health insurance plan for low-income citizens including fee-for-service 
and managed care providers, approval rates at the national, state, and 
institutional levels followed by evidence from different studies on the cost-value 
of expansion of Medicaid restrictive approval criteria.  
The next part is devoted to geographical accessibility describing the 
barriers encountered by patients to reach HCV services in the US.  
The acceptance dimension is then elaborated on from both the provider 
and patient aspects including: stigmatization in HCV care, attitudes of providers 
toward HCV patients, and patients’ cultural acceptance and awareness 
concerning HCV treatment.  
The last part concerning the dimensions covers accommodation. It 
provides the strategic guidance and best practices for a successful HCV model of 
care that can ultimately accommodate the needs of patients and it factors in the 
barriers. It elaborates on this with concrete examples and illustrations of how 
successful US models were implemented. 
The fourth section is devoted for Kentucky special profile. It begins with 
presenting the volume and characteristics of HCV patients in Kentucky. It then 
describes the Kentucky Medicaid program approval criteria, and finally the 
characteristics of HCV patients in the study setting.  
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This review is then concluded with a fifth section summarizing it and 
offering the implications of this study within the current literature on DAA 
treatment for HCV. Finally, the sixth section gives the empirical and theoretical 
bases for this study and its expected results.  
I- Hepatitis C Virus Background 
Discovery 
In 1975, a new condition of chronic liver inflammation among blood 
transfusion recipients was reported without association with neither hepatitis A 
virus (HAV) nor hepatitis B virus (HBV) infections. This condition was labelled 
non-A, non-B hepatitis until 1989 when the HCV was given its name as a 
distinguished liver virus after successful cloning (Bukh, 2016).  
Virology 
HCV is a ribonucleic acid (RNA) enveloped single-stranded virus. It 
belongs to the flavivirus family that includes hepatitis G, Yellow fever, and 
Dengue fever viruses (Bukh, 2016). The virus has been detected in most body 
fluids and tissues including saliva, tears, breast milk, vaginal secretions, and 
seminal fluid (Patrick, Buxton, Bigham, & Mathias, 2000). The virus has 
exceptional virological criteria that significantly challenge its control. Scientific 
efforts to grow HCV in culture has been unsuccessful. The virus replication is 
extremely rapid producing more than 10 trillion new virion particles per day, even 
after chronicity, hindering the human body immune-mediated control (Lauer & 
Walker, 2001). In addition, HCV possesses a high genetic diversity resulting in a 
major challenge for vaccine and pan-genotypic drug therapy development (Timm 
& Roggendorf, 2007).  
HCV is sub-classified into seven genotypes and several sub-genotypes 
based on the viral genome phylogenetic and sequence analysis. Genotype 1 is 
the most common worldwide comprising 46% of all HCV infections followed by 
genotypes 3 with 22%. Genotypes 2 and 4 are fairly equal in their distribution; 
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about 13% each (Gower, Estes, Blach, Razavi-Shearer, & Razavi, 2014). Only 
one historical genotype 7 infection was isolated from a Central African immigrant 
in Canada (Messina et al., 2015). 
Genotype 1 is highly prevalent in North and South America, Europe, and 
Australia, ranging from 53 to 71% of all cases. Genotype 3 is the leading in Asia 
with almost 40% of all HCV infections while Genotype 4 accounts for 71% of 
infections in the Middle East and North Africa (Gower et al., 2014). 
Transmission 
The HCV infection transmission is blood-borne. The most common 
methods of transmission are: transfusion of contaminated blood or blood 
products; and percutaneous blood exposure either via medical procedures, 
tattooing and piercing practices, or sharing a contaminated injection or intranasal 
drug use device (Manns et al., 2017). The transmission risk of HCV from a single 
percutaneous blood exposure is intermediate (2.7-6%), compared to HBV (19-
30%) and human immunodeficiency virus (HIV) (0.3%) risks (Patrick et al., 2000). 
Mother to infant HCV transmission is less frequent while sexual transmission is 
rare (Manns et al., 2017). 
Historically, the most common reported method for HCV transmission is 
blood transfusion prior to the establishment of universal blood screening in 1992 
(Lauer & Walker, 2001). It is estimated that 3 million Americans in the baby 
boomer generation, born between 1945 and 1965, contracted HCV infection 
through blood, blood products, tissue, or organ donation. Currently, the 
probability is less than 1 in 1 million blood transfusions may transmit HCV, 
shifting the most common method of transmission to injection and intranasal drug 
use practices (Monina Klevens, Hu, Jiles, & Holmberg, 2012).  
Prevention 
Reducing the risk of exposure in medical procedures, tattooing and 
piercing practices, and injection drug use in addition to protected sexual contact 
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are the primary prevention methods for HCV (World Health Orgnaization, 2016). 
There is no prophylactic vaccine for HCV due to the unsuccessful trials till date 
for antibody-based virus neutralization and T-cell based virus elimination from 
infected cells (Bukh, 2016). A T-cell vaccine is currently under trial aiming at 
preventing persistent infection with HCV (Swadling, Klenerman, & Barnes, 2013).  
Secondary prevention strategies for HCV include early detection of cases, 
raising awareness and counselling on treatment options, and immunization 
against HAV and HBV. Tertiary prevention mandates early treatment with 
antiviral drugs beside regular monitoring and management of chronic liver 
affection (World Health Orgnaization, 2016).  
Natural History 
Infection with HCV results in an acute phase within 2 to 24 weeks; 
however, acute infection passes undiagnosed in about 80% of cases either for 
being asymptomatic or association with mild general symptoms. Manifest acute 
symptoms may include fever; fatigue; loss of appetite; nausea and vomiting; 
abdominal pains; dark urine and clay colored stool; joint pain; or jaundice i.e. 
yellow eye color. Fulmination of the acute phase is extremely rare (World Health 
Orgnaization, 2016).  
Strong immune response in 15-45% of cases spontaneously clear the 
HCV within 24 weeks while 55- 85% will acquire persistent viremia and chronic 
infection with potential progress to liver damage in the form of cirrhosis or liver 
cell failure between 15 -30% within two or three decades (World Health 
Orgnaization, 2016). Liver cirrhosis is associated with an annual 1 to 4% risk of 
HCC. Beside liver affection, various body organs can be affected by HCV due to 
its autoimmune response. These affections are collectively called extrahepatic 
manifestations (EHM) (Lauer & Walker, 2001). 
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Prevalence and Incidence 
Hepatitis C virus infection represents a worldwide viral pandemic five 
times more prevalent than type 1 human immunodeficiency virus (HIV-1) (Lauer 
& Walker, 2001). The global prevalence of HCV antibodies is estimated at 1.6% 
of the world population corresponding to 115 million people living with HCV 
(Gower et al., 2014). In the US, HCV tops the list of prevalent blood-borne 
infections with estimated 3.6 million Americans carrying antibodies to the virus 
and 2.7 million chronically infected based on the National Health and Nutrition 
Examination Survey (NHANES) 2003 to 2010 data (Denniston et al., 2014). 
Some higher estimates claim that Americans with previous exposure are 4.6 
million while those with chronic infection are 3.5 million people (Edlin, Eckhardt, 
Shu, Holmberg, & Swan, 2015). Reasonable lower estimates factored in the 
increasing mortality from HCV pointed to 3.2 million antibody carrying Americans 
(Holmberg, Spradling, Moorman, & Denniston, 2013). 
A global comparative study published in 2014 estimated that 1.3% of adult 
Americans has HCV antibodies corresponding to 3,347,000 people and the 
national viremic rate i.e. chronicity is 76.9% resulting in 1% chronically infected 
adults equivalent to 2,575,000 Americans. Based on these estimates, the 
genotypic distribution of HCV in the US is: 46.2% of cases has genotype 1a, 
26.3% genotype 1b, 10.7% genotype 2, 8.9% genotype 3, 6.3% genotype 4, 
1.1% genotype 6, and 0.5% mixed genotypes (Gower et al., 2014). 
The US Centers for Disease Control and Prevention (CDC) surveillance 
system reported a steady increase in acute HCV infections across the nation 
from 853 cases in 2010 to 2,194 cases in 2014 projecting a 30,500 real new 
cases in the United States in 2014 (Centers for Disease Control and Prevention, 
2016). 
Morbidity and Mortality Burden 
Hepatitis C virus infection is the leading cause of chronic liver disease and 
HCC in the United States. Moreover, liver cell failure from HCV is the most 
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common indication for liver transplantation (LT) not only in the US but also in 
North America and Western Europe (Ditah et al., 2014).  
A large scale US study on 10 million HCV test results retrieved from 2010 
to 2013 showed that 5% of the 2.6 million patients with data on their liver 
conditions are chronically infected with the virus. About 23% of the chronically 
infected cases, and 27% among the baby boomer age group, showed signs of 
advanced fibrosis or cirrhosis at the first diagnosis compared to only 3% among 
the uninfected cases with HCV (Monina Klevens et al., 2016).  
Between 2001 and 2010, HCV patients’ healthcare utilization data 
revealed that they payed annually more than 2.3 million outpatient visits, 73,000 
visits to emergency departments, and 475,000 hospitalizations (Galbraith et al., 
2014). Extrahepatic HCV manifestations alone lead to an annual 15% increase in 
HCV patients’ hospitalization rate (Monina Klevens et al., 2012). 
The mortality from the HCV dramatically increased in the US from 11,051 
associated deaths in 2003 to 19,368 in 2013; an average annual increase by 865 
deaths equivalent to 6.2% increase per year (Ly, Hughes, Jiles, & Holmberg, 
2016). In 2014, the number of deaths associated with the virus reached 19,659, 
more than half of this number occurred among persons aged between 55 and 64 
years. This tremendous increase is the highest among the infectious diseases in 
the US and exceeds the mortality from more than 60 other infectious diseases 
combined (Centers for Disease Control and Prevention, 2016). 
Economic Burden 
The economic burden of HCV results from either the direct costs 
associated with its liver disease sequelae and extrahepatic manifestations; or the 
indirect costs from chronic HCV patients’ productivity loss (Younossi, Birerdinc, & 
Henry, 2016). In 2011, the total healthcare cost associated with HCV was 
estimated at $6.5 billion. Based on this estimation, it is projected that this cost will 
reach $9.1 billion in 2024. The highest expenditures are expected from 
decompensated cirrhosis (46%), compensated cirrhosis (20%), and HCC (16%) 
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(Shah, Younossi, & Opsha, 2015). The annual healthcare cost associated solely 
with HCV EHM is estimated to be $1.5 billion (Younossi, Park, Henry, Adeyemi, 
& Stepanova, 2016). The indirect economic burden of HCV patients’ productivity 
loss is estimated to be $7.1 billion per year mainly due to work absenteeism 
(Baran et al., 2015). 
II- Access Models for Hepatitis C Treatment 
Applying theoretical models to assess influencing factors, either enabling 
or hindering, on access to health services is widely debated in the literature. 
Health services researchers continuously modify the historical access conceptual 
models to contextualize different health problems, respond to the advances in 
health services delivery, and address different influencing determinants 
interacting with health services provision (Ricketts & Goldsmith, 2005).  
In their universally applied and critically researched model, Penchansky & 
Thomas (1981) defined access to health services as a process aiming at an 
ultimate fit between the demand; i.e. clients’ needs, and the supply; i.e. the 
healthcare system providing health services. To achieve this goal, Penchansky & 
Thomas (1981) proposed a five-dimension model to conceptualize access 
barriers. In this model, the first dimension is the “availability” where the clients’ 
volume and types of needs are addressed by responsive services and resources 
including providers, specialized programs, facilities, medicines, and equipment. 
The second dimension “affordability” encompass costs of services facing the 
clients' ability to pay and their health insurance coverage. The third dimension 
“accessibility” pertains to the client geographical distance and time from the 
needed health services. Fourth, the “acceptability” dimension represents the 
mutual expectations and acceptance of attitudes and personal characteristics 
between the client and the provider. The fifth dimension, “accommodation”, refers 
to the model of care that health services apply, including organization of 
resources and administrative procedures, to accommodate the clients’ collective 
needs from all dimensions (Penchansky & Thomas, 1981).  
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Peters et al. (2008) contributed to the original Penchansky model by 
plotting in their framework two key determinants influencing the aforementioned 
access dimensions: policy and macro-environment as an upstream level 
determinant; in addition, the client’s household characteristics and individual 
vulnerability as a downstream level determinant. Jacobs, Ir, Bigdeli, Annear, & 
Van Damme (2012) identified the key barriers to these dimensions.  For the 
availability dimension, supply side barriers include lack of needed services; e.g. 
lack of availability of medicines and equipment; and incompetency and low 
motivation of providers. The demand side barriers revolve around proper client 
awareness and perceived need. Affordability supply barriers are the direct, 
indirect, and informal costs of services; and differences between public and 
private, profit and nonprofit, health facilities. The client’s ability to pay, opportunity 
costs, insurance coverage, and payment schemes for services influenced by the 
availability of cash flow within the society are the demand side hindering barriers. 
Geographical accessibility depends on service location and the transportation 
means, time, and costs encountered by the client. Acceptance requires proper 
provider-client relationship where the provider attitude meets the clients’ 
expectations and build trust. Expected barriers include limited client awareness, 
information asymmetry between the provider and client, stigma, and low 
assertiveness from the provider side. Accommodation supply barriers include 
inadequate continuity of care; e.g. late referrals to specialized services, 
inconvenient working hours, prolonged waiting times, and improper integration 
with other needed health services by the clients. (Jacobs et al., 2012; Peters et 
al., 2008).  
Wagner et al. (2001) proposed a specialized chronic care model to guide 
chronic illnesses care. This model is composed of six components and was 
developed from practice-based results of a nationwide project involved 104 
health services organizations in the US. The first component “Healthcare 
Organization” emphasizes that in order to improve quality of care the health 
services facility should gain support and commitment from its leaders. In the 
second component, “Community Resources”, the model underscores the role of 
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community participation in cost-efficient expansion and improvement of access to 
chronic illnesses services. The fourth component “Delivery System Design” 
complements the second component by highlighting the role of community health 
workers and case managers in counseling, behavioral change, adherence to 
treatment, and efficient use of resources. The “Self-Management Support” 
component maximizes the patient potentials to self-manage his or her condition 
through individual or group support, encouragement, and self-confidence 
building. The “Decision Support” component requires integration of chronic 
illness treatment within a comprehensive care provision. The sixth component, 
Clinical Information System, provides the tool for decision support and integration 
of care using patients’ medical records (Wagner et al., 2001).  
Sbarigia et al. (2016) applied the concepts of access on HCV studies to 
develop a conceptual framework for HCV management outcomes. Their linear 
framework starts with the healthcare system structure and the patient 
characteristics as key input predictors for the process of care; the intermediate 
predictor. Collectively, all these predictors contribute the client outcomes. The 
healthcare system structure mirrors the supply side of all access dimensions in 
the Penchansky model with special consideration to the provider and model of 
care characteristics. Client characteristics apply across the board on the demand 
side including social, demographic, financial, behavioral, and clinical 
characteristics. The process of care is the performance centered element 
reflecting the “quality of health services” core in the Peters model. It underscores 
the effectiveness of management of HCV infection according to the standardized 
guidelines of care provision. The client outcomes vary from utilization, patient 
reported outcomes, to ultimately achieving cure (Sbarigia et al., 2016). In HCV 
management, cure is indicated by sustained virological response (SVR) defined 
by the absence of detectable HCV RNA in serum; i.e. 50 IU/mL or less for 24 
weeks after the end of treatment (Chevaliez & Pawlotsky, 2005). 
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Collectively from these general and focused conceptual frameworks on 
HCV, the proposed framework in figure 1 offers a conceptual outline for 
assessing access to DAA treatment in the following part of this review.
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Figure 1. Conceptual framework proposed for assessing access to hepatitis C directly acting antivirals [Adopted 
from: (Penchansky & Thomas, 1981; Peters et al., 2008; Sbarigia et al., 2016; Wagner et al., 2001)] 
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III- Dimensions and Influencing Factors on Access to Hepatitis C 
Directly Acting Antivirals in the United States 
A- Availability 
Hepatitis C Virus Infection Diagnosis 
On suspecting HCV infection, the first step is to identify previous infection 
using serological essays that detect HCV antibodies. While the laboratory-based 
HCV antibody test is the most reliable; rapid tests are available for real-time 
screening. In positive cases, a molecular test for HCV RNA is needed to confirm 
chronic infection and to quantify viral particles load. Some cases, 15-45%, with 
positive antibody tests show undetectable HCV RNA due to spontaneous 
clearance of the infection by their immune response. Viral genotyping is another 
step in the diagnosis that help chose proper treatment regimen and predict its 
outcome (World Health Orgnaization, 2016). 
For disease staging and liver affection, a histologic evaluation of liver 
biopsy is the gold standard to assess fibrosis level i.e. liver damage; exclude 
other pathologies; and predict the disease progression. Other less invasive 
laboratory and radiological investigations e.g. elastography are widely used for 
assessment of liver function and disease staging (Manns et al., 2017).  
Advances in the Curative Treatment for Hepatitis C Virus Infection 
The timeline of HCV antiviral treatment begins in 1986 before the virus 
discovery. Non-A non-B hepatitis patients were recommended three injections of 
recombinant IFN-α per week. In the following decade, the IFN-α dose and 
duration increased until it was combined in 1998 with Ribavirin (RBV), a non-
specific oral antiviral. For the following decade, from 2001 to 2011, the 
standardized treatment of HCV was a combination of a modified long-acting 
PEGylated interferon (PEG-IFN) with RBV. This treatment regimen was applied 
for 12-72 weeks and showed a wide range of treatment efficacy i.e. SVR, 
between 40 and 80% depending on the virus genotype. Considerable clinical and 
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psychological adverse effects of this standardized regimen hindered treatment 
adherence and outcomes (Manns et al., 2017).  
In May 2011, the FDA approved the first-generation of DAAs combination 
Boceprevir and Telaprevir, to boost the efficacy of the PEG-IFN and RBV 
protocol. The SVR of this quadruple regimen reached 68-75% in naive cases and 
59-88% in treatment experienced cases. The game changer DAA Sofosbuvir has 
been approved by the FDA in December 2013 as the first second-generation 
DAA to be used in combination with PEG-IFN and RBV or with RBV alone and 
showed SVR rates exceeding 85% (Ponziani et al., 2017).  
After the unprecedented success of Sofosbuvir, the competitive research 
on discovery of IFN-free regimens aiming at maximizing SVR rates for different 
genotypes and liver conditions while reducing adverse effects evolved rapidly. 
The FDA approved several DAAs to be combined with Sofosbuvir:  Simeprevir 
and Ledipasvir for genotype 1, Daclatasvir for genotype 3, and Velpatasvir. 
These new combinations reported SVR above 90% for the first time in the HCV 
history (Ponziani et al., 2017).   
Since July 2015, the FDA approved novel DDAs to be prescribed without 
Sofosbuvir including Paritaprevir, Ritonavir and Ombitasvir, in association with 
Dasabuvir for genotype 1 and without it for genotype 4. Most recently, in January 
2016, the FDA added to the Sofosbuvir-free regimens approval list the 
Elbasvir/Grazoprevir combination (Ponziani et al., 2017). In June 2016, the FDA 
approved Sofosbuvir/Velpatasvir as a combined single tablet regimen for all 
genotypes without the need of RBV (American Liver Foundation, 2016).   
In accordance, the advancements in DAAs led to the availability of 
standardized IFN-free all-oral protocols for all genotypes and liver disease stages 
and comorbidities; administered for relatively short duration between 8 and 24 
weeks; with high safety and low adverse effects; and achieving cure rates 
reaching 98% even in historically difficult to cure patients with the IFN-based 
therapy (Manns et al., 2017).  
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Given the high efficacy and tolerability of DAAs compared to the old IFN-
based therapy, the all-oral DAAs therapy has been established as the 
standardized curative treatment for all HCV genotypes and disease stages. 
Different protocols are recommended and continuously updated by the American 
Association for the Study of Liver Diseases (AASLD) to provide the best options 
for each category of patients. These protocols recommend either using a specific 
single or combined DAAs with and without RBV (American Association for The 
Study of Liver Diseases, 2016).  
Health Benefits of Directly Acting Antiviral Treatment 
Clinical outcomes from DAAs are maximized with achieving SVR; 
however, all patients at different stages of the disease gain clinical benefits from 
antiviral treatment in two aspects: liver function and prognosis (Rodriguez & 
Reynolds, 2016; Younossi, Birerdinc, et al., 2016). The majority of early liver 
affection patients who achieve SVR develop significant improvements in their 
liver functions and reversal of mild fibrosis over time. Advanced fibrosis and 
cirrhotic patients show improved liver function as well with risk reduction of liver 
cell failure and HCC; need for LT; post transplantation infection recurrence; and 
increased life expectancy (Rodriguez & Reynolds, 2016).  
Chhatwal et al. (2016) projection study anticipated the current DAAs would 
prevent 8,600 cases of decompensated cirrhosis, 5,400 cases of HCC, 900 LTs, 
and 9,700 related mortalities, from 2015 through 2050. In addition, they would 
reduce the HCV prevalence in the United States by more than 80% by 2040 if the 
treatment initiation rate remained unchanged.  
The same study projected the morbidities and mortality from 2015 to 2050 
that would be associated with assumed three scenarios: all-oral DDAs regimen, 
old IFN-based regimen, and no treatment for HCV infection. Findings revealed a 
significant difference favoring the clinical outcomes of the all-oral DAAs. The 
projected cumulative incidence for decompensated cirrhosis is 203,000 for the 
first, 468,000 for the second, and 665,000 for the third scenarios respectively. 
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Regarding the cumulative incidence of HCC, the results’ estimates pointed to 
157,000, 305,000, and 415,000 cases respectively for the three scenarios. The 
number of LTs would be 32,000, 53,000, and 65,000; and the cumulative number 
of deaths associated with HCV infection are: 320,000, 587,000, and 776,000 as 
ordered previously (Chhatwal et al., 2016).  
Early treatment has been proved beneficial in reducing morbidity and 
mortality from the chronic HCV infection. A study on 187,860 chronic HCV 
patients in a Veterans Health Administration (VHA) center showed that treatment 
initiation in no to mild fibrosis patients would reduce morbidity by 41% and 
mortality by 36%. Comparing non-advanced fibrosis to advanced fibrosis 
patients, the study found that the non-advanced group would develop 34% 
morbidity and 45% mortality risk reduction on treatment initiation while the 
advanced fibrosis group would develop only 11% and 25% risk reductions 
respectively (McCombs, Tonnu-MiHara, Matsuda, McGinnis, & Fox, 2015).  
The DAAs opened a great opportunity for HCV eradication not only for 
their curative role, but also for their importance in prevention of transmission. 
Low serum viral load reduces the risk of HCV transmission significantly. This 
principal has been established as a successful strategy in HIV prevention 
resulting in worldwide availability of antiretroviral therapy (ART) (National 
Academy of Sciences, 2016).  
In addition, two challenges for HCV regular primary prevention methods 
favor the investment in DAAs as prevention. First, there is no available effective 
vaccine for HCV till date. Second, transmission prevention strategies among 
people who inject drugs (PWIDs) e.g. syringe exchange, show limited success 
compared to the escalating incidence among this high risk group. Consequently, 
the maximum benefit at population level from DAAs for incidence and prevalence 
reduction will be gained if targeted high risk groups including new and young 
PWIDs and prisoners. For reduction of morbidity and mortality, the benefit will be 
at individual level on targeting old PWIDs with low or no injection activity as they 
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have low risk for infection transmission (Grebely, Matthews, Lloyd, & Dore, 
2013).  
Nevertheless, a major barrier for using DAAs as a cost-effective 
prevention strategy in high risk groups is the risk of reinfection (National 
Academy of Sciences, 2016). The collective estimate for risk of reinfection post 
SVR from thirteen studies done on PWIDs and men having sex with men (MSM) 
ranged between 0.9 and 6.1% per 100 person-year. However, these estimates 
are jeopardized by the probability of relapse after the initial SVR and the 
difference in intensity of high risk practices and incidence rate among the 
populations of these studies (Grady, Schinkel, Thomas, & Dalgard, 2013).  
Provider Availability and Requirements for Managing Hepatitis C with 
Directly Acting Antiviral Treatment 
The DAAs are specialty drugs that require prescription and full 
management under supervision of a clinician. Prescriber limitations according to 
Medicaid requirements in fifteen states mandates a clinical specialist; i.e. 
gastroenterologist, hepatologist, or infectious diseases specialist for HCV 
treatment prescription. In fourteen states, Medicaid opens the door for non-
specialist clinicians to prescribe or follow hepatitis C patients in consultation with 
a specialist, while only thriteen states have no Medicaid prescriber limitations on 
HCV treatment (Barua et al., 2015). 
Supporting this restrictive policy, a study conducted by the CDC on the 
distribution of different providers ordered 1,112,105 HCV laboratory tests 
revealed the predominance of specialists over non-specialists in HCV care. The 
overall test to provider ratio was 8.1, the highest ratio was for hepatologists 
(26.1) followed by infectious diseases specialists (23.7), internal medicine 
specialists (7.3), family medicine practitioners (6.4), and general practitioners 
(6.6) respectively (M. Klevens, Pugh, Ward, Thakare, & Holmberg, 2014).  
To alleviate this problematic barrier, a joint letter signed by eight clinical 
associations led by the American Academy of Family Physicians urged the 
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Centers for Medicine & Medicaid Services (CMS) in April 2016 to rely on the 
expertise of the provider rather than restricting prescription to specialists 
considering the latter shortage in rural areas in the US. This policy change would 
improve access to safe and effective DAAs tremendously and ensure equitable 
access in rural area where 20% of American citizens live and only 9% of 
physicians practice. The letter final message to the CMS emphasized that 
Medicare, the federally subsidized health insurance for elderly citizens above the 
age of 65 and disabled younger citizens, with its closely tied programs to DAAs 
prescriptions: Medicare Advantage and Medicare Part D, and Medicaid should 
not hinder physicians from treating HCV according to their specialty (American 
Academy of Family Physicians, 2016).  
Guidance on Provision of Directly Acting Antiviral Treatment 
Several organizations developed guidance reports, recommendations, and 
action plans emphasizing the importance of identification and treatment of HCV 
with DAAs. The US Preventive Services Task Force (USPSTF) recommends 
hepatitis C screening for high risk groups of HCV transmission including 
individuals who: had history of injection or intranasal drug use, received tattoos 
under unregulated maneuvers; received blood or blood products prior to 1992; 
were born between 1945 and 1965; or were born to an infected mother. Due to 
the severe complications of comorbidity, HCV annual screening is recommended 
for people living with HIV (Moyer & U.S. Preventive Services Task Force, 2013) 
Complementing these recommendations, the American Association for the 
Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America 
recommend early treatment with IFN-free regimens for all patients with chronic 
HCV infection except patients with short life expectancy. This exclusion is not 
only for antiviral treatment but for other radical management interventions 
including LT. However, the two societies prioritize treatment for high risk 
morbidity and mortality patients, particularly those with advanced fibrosis or 
compensated cirrhosis i.e. Metavir fibrosis scores F3 and F4.  Second in raw are 
the patients with high risk for complications especially those with F2 Metavir 
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fibrosis score, HIV or HBV coinfection, other coexisting liver disease, and insulin 
resistance diabetes mellitus (American Association for The Study of Liver 
Diseases, 2016).  
Following the AASLD guidelines on early and inclusive treatment for 
almost all HCV patients, the American College of Preventive Medicine issued a 
position statement on Hepatitis C Virus infection. The linkage to care 
recommendations of this position statement pointed to four mandatory steps for 
HCV discovered patients: early diagnosis confirmation, quantitative HCV RNA 
test, genotype identification, and evaluation for DAAs eligibility. Responsibility of 
developing quality and accountability measures for linkage to care should be 
delegated to the National Committee for Quality Assurance, the Joint 
Commission, and CMS (Allison et al., 2016).  
In the same direction, the National Viral Hepatitis Action Plan for 2017-
2020 highlighted in its second goal “Reduce Deaths and Improve the Health of 
People Living with Viral Hepatitis” the importance of improving access to HCV 
treatment. To achieve this goal, the action plan called for building the capacities 
of human resources needed for diagnosis and treatment, special focus on 
improving HIV/HCV and PWIDs access to treatment, expansion of access to 
preventive and curative services in incarceration settings, monitoring treatment 
and its impact, and advancing research for patients’ identification and cure 
(DeSalvo, Scott, Wolitski, & Dan, 2017).  
Hepatitis C Infection Treatment Cascade and Initiation Rates 
Based on NHANES data that estimates 3.2 million chronically infected 
Americans with HCV i.e. potentially eligible for treatment, Holmberg et al. (2013) 
developed a treatment cascade for HCV patients at the national level. In this 
cascade, about half of the chronically infected patients i.e. 1.6 million populations 
were discovered, 38% corresponding to 1.2 million were referred to care, while 
the treatment initiation rate ranged from 7 to 11% i.e. 220,00 to 360,000 patients. 
These numbers imply that 18.33% to 30% of the patients referred to care 
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succeeded in initiating treatment. The estimated cured patients ranged from 
170,000 to 200,000 i.e. 5-6% of the chronically infected patients. (Holmberg et 
al., 2013). 
Yehia, Schranz, Umscheid, & Lo Re, (2014) developed another cascade 
(figure 2) starting with 3.5. million infected population considering that NHANES 
estimations didn’t factor in some high risk groups e.g. homeless and incardinated 
population. Accordingly, 1.74 million (49.8%) were diagnosed and aware of their 
status out of the 3.5 million, 1.51 million (43.3% of the total) are aware and 
covered by insurance that give them an access to hepatitis C services. Further, 
952,726 patients (27.2% of the total) are estimated to be aware, possess access, 
and confirmed with HCV RNA test. Adding a confirmatory liver biopsy, the latter 
group narrows down to 581,632 (16.6%) patients. An estimated 555,883 persons 
(15.9%) passed all previous steps and were prescribed treatment. The final step 
in Yehia et al. cascade points to 326,859 patients (9.3%) achieved SVR. These 
numbers imply that out of the patients who were aware, possess access, and 
confirmed with HCV RNA test; the proportion of the patients who were prescribed 
the treatment was 58.35% meanwhile the proportion of the patients who 
achieved SVR was 34.30%. However, the last two steps in this cascade don’t 
give an answer for the question: how much patients between the treatment 
prescription (555,883 patients) and SVR (326,859 patients) steps didn’t initiate 
treatment in the first place, initiated but didn’t complete their regimen, or 
completed treatment as prescribed but were resistant to therapy (Yehia et al., 
2014).  
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Chhatwal et al., (2016) estimated that in 2015 the HCV infected patients 
who were aware of their status and had insurance coverage were 923,000, 
compared to the 1,514,600 million estimates of the previous study. The same 
study estimated from the reported DAAs market sales that the number of patients 
who initiated treatment in 2015 were 280,000; a sharp increase from the 150,000 
patients estimate in 2014. These numbers reveal that an estimated 33.34% of 
the theoretically prepared patients for referral (923,00 patients) initiated DAA-
based treatment in 2015 (Chhatwal et al., 2016).  
The Veterans Health Administration (VHA), the largest provider of HCV 
care nationwide, had in 2011-2012 DAAs regional initiation rates ranging from 3-
7%, the lowest facility initiation rate was below 1% and the highest had 17% 
initiation rate (Belperio, Backus, Ross, Neuhauser, & Mole, 2014). In 2013, the 
VHA HCV treatment cascade showed higher rates compared to the national 
rates. The VHA reported 233,898 infected patients with HCV, 181,168 (77%) 
were diagnosed, 160,794 (69%) were linked to care, 39,388 (17%) initiated 
treatment and 15,983 (7%) were treated with HCV antivirals, and 15,983 (7%) 
achieved SVR. These numbers point to a 24.5% initiation rate among the 
patients linked to care (Maier, Ross, Chartier, Belperio, & Backus, 2016). In 
2015, Noska, Belperio, Loomis, O’Toole, & Backus (2017) estimated that the 
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Figure 2. Treatment cascade for hepatitis C virus infected 
population in the United States (Source Yehia et al., 2014)
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number of veterans with HCV infection was 220,605 (32,449 homeless and 
188,156 non-homeless). Confirmed diagnosis with HCV RNA was found in 
89.6% of homeless vs. 77% of non-homeless veterans. Homeless veterans 
linked to care represented 79.5% and non-homeless were 72.4%, Treatment 
initiation rate was 22.9% in the homeless group compared to 31% in the non-
homeless group. About 15.5% of the homeless achieved SVR vs. 22.8% of the 
non-homeless (Noska et al., 2017).  
The 2016 US Medicine's Use and Spending report proposed a close 
number for 2015 treatment initiation rate (279,000 patients) while it estimated 
170,000 patients in 2014. The total number of patients who initiated treatment in 
these two years, 2014 and 2015, is 5 times the number of patients who initiated 
treatment in the prior three years combined (IMS Institute for Healthcare 
Informatics, 2016b). Drug specific estimates in these two years show that 
140,000 and 200,000 patients initiated treatment with either Gilead Sciences 
products Harvoni® or Sovaldi® in 2014 and 2015 respectively. The more recently 
approved AbbVie’s Viekira® in December 2014 is estimated to be used by 
12,000 patients initiated treatment in 2015 (National Academy of Sciences, 
2016).   
Organizational based studies show a wide range of variation in treatment 
initiation rates. Stepanova & Younossi (2015) surveyed 10,799 and 11,840 adult 
participants from the NHANES 2005–2008 and 2009–2012 and found that HCV 
infected participants represented 1.19% and 0.94% in the two surveys 
respectively. The potential access, considering insurance coverage and regimen 
specific eligibility, to HCV treatment increased from 35.1% for the IFN-based 
regimen to 66.6 % for all-oral DAAs (Stepanova & Younossi, 2015). Ditah et al., 
(2015) found that 502 (1.3%) of total 38,025 adult participants sampled from 
NHANES surveys 2001-2010 were infected with HCV. Out of the 205 participants 
followed by the study, 67 (40.4%) reported HCV treatment recommendation by a 
provider and only 18 of them (26.9%) initiated treatment (Ditah et al., 2015). 
Another study worked on the same NHANES surveys recruited 203 participants 
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and found that about half of them (101 participants) were aware of their HCV 
infection prior to their participation in the NHANES survey while only 17% (34 
participants) initiated treatment (Z. Younossi, Stepanova, Afendy, Lam, & Mishra, 
2013).  
A follow up survey with a sample of NHANES participants from 2001 
through 2008 showed that 13% of respondents received a treatment for their 
HCV condition (Denniston et al., 2014). A study on a commercial database of 
73,665 insured patients from 2009 to 2013 showed that treatment initiation rate 
was 10.1% (Vutien, Hoang, Brooks, Nguyen, & Nguyen, 2016).  
Secondary data analyses conducted on the records of 13,000 patients in 
the Chronic Hepatitis Cohort Study (CHeCS) showed that 18% of the study 
cohort were infected and only 36% of this portion were aware of their condition 
and initiated a treatment for HCV from 2001 to 2010 (Holmberg et al., 2013).  
Results from the New York City Department of Health Check HepC 
Program between mid-2012 to mid-2013 revealed that 19% (880/4,751 
participants) had positive HCV antibody test, 512 participants had a confirmation 
with HCV RNA i.e. treatment eligible, 435 (85% of confirmed cases) were linked 
to care, 157 (36%) were checked at a specialized clinic. Forty-seven cases of the 
157 checked were identified as good candidates for treatment (30%) and only 14 
(30% of the identified candidates) initiated treatment, 3 of them didn’t complete 
treatment, 5 didn’t follow after completion, and 6 completed and had reported 
SVR. These numbers mean that 29.8% of the identified eligible (157 patients), 
who could be comparable to the current linked patients to DAAs treatment, 
initiated treatment (Ford et al., 2017).  
Future estimates for DAAs demand based on the 280,000 initiation rate of 
2015 anticipate that the number of patients aware of their condition and have 
insurance coverage i.e. ready candidates, will fall below the treatment capacity in 
2019 on condition that this capacity will remain constant and all stages of liver 
disease are accepted by insurance. This ambitious estimation projects the 
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number of these ready candidates to be 55,000 in 2020 and 30,000 in 2030 
(Chhatwal et al., 2016).  
Characteristics of Hepatitis C Infection Patients 
1- Sociodemographic Characteristics 
The CDC national reports from 2010-2014 pointed to a higher incidence of 
hepatitis C new cases among Caucasians and non-urban residents (Centers for 
Disease Control and Prevention, 2016). The NHANES results from 2003 to 2010 
revealed that hepatitis C infected persons were more likely to be aged between 
40 to 59 years, males, and of African American race compared to persons 
without the virus (Denniston et al., 2014).  
Over the period 2009-2013 a commercial multi-state database analysis 
showed that Caucasians had the highest treatment initiation rate (10.7%) 
followed by African Americans (8.8%), Hispanics (8.8%), and Asians (7.9%) 
(Vutien et al., 2016). A VHA study analyzed patients’ data in the first 16 months 
of all-oral DAAs approval revealed that African American patients were 21% less 
likely to initiate treatment compared to Caucasians. In this study no significant 
difference was found among different genders or age groups (Kanwal et al., 
2016).  
A study on 100 baby boomers visited a Michigan health services group of 
21 clinics from mid-2014 to mid-2015 showed that the differential distribution of 
patients who initiated treatment were 22.6% of males, 42.1% of females, 28% of 
African Americans, 36% of non-African Americans, 27% of lower income 
patients, 54.5% of higher income patients. The odds of females were 2.3 times 
the males for treatment initiation (Bourgi, Brar, & Baker-Genaw, 2016).  
The distribution of New York City Department of Health Check HepC 
Program 4,751 patients recruited for linkage to care and treatment showed that 
55% were born after 1965, 44% were baby boomers, and 4.9% were born before 
1945. Hispanic patients comprised 48.6%, while African Americans represented 
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40% and Caucasians were 8.6%. Beside patients with unreported gender, males 
represented 55.3% while females represented 43.3% of the program participants 
(Ford et al., 2017).  
2- Behavioral Characteristics 
Substance abuse is the salient risky behavior among the majority of HCV 
patients. Based on the NHANES data, in 2011 the HCV infection rate among 
PWIDs was 43,126 per 100,000 persons aged 40-65. This rate is obviously 
higher if compared to the HIV infection rate of 2,147 per 100,000 PWIDs in 2010 
(Lansky et al., 2014). Some estimates are pointing to an extremely high 
incidence of HCV infection reaching 40 per 100 person-years supported by the 
2009 National viral hepatitis surveillance results that showed 56% (241 of 432) of 
acute HCV cases reported injection drug use within the previous six months (R. 
M. Klevens, Hu, Jiles, & Holmberg, 2012). Higher estimates were found in a 
smaller scale study conducted in Connecticut between 2013 and 2015 where the 
HCV infection rate among PWIDs reached 60% (Butner et al., 2017). 
Older estimates are lower, a study estimated that from 1999 to 2002 the 
prevalence of HCV infection among young PWIDs aged from 20 to 59 was 
slightly above 45% (Armstrong et al., 2006).  
Disparity in DAA treatment initiation has been found disadvantaging 
PWIDs. A multi-center study on HCV patients on DAA treatment between 
January-August 2015 found that patients who were not involved in injection drug 
use had significantly higher odds for DAAs initiation (Hautamaki et al., 2016).  
3- Clinical Characteristics  
Klevens et al., (2016) in their 2010-2013 study found that among 150,475 
patients diagnosed with HCV there were 59,933 (39.8%) with no or mild fibrosis, 
55,524 (36.9%) with moderate fibrosis, and 35,018 (23.3%) with advanced 
fibrosis or cirrhosis. 
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Between January 2013 and August 2014, a specialized clinic for co-
infected patients with HIV/HCV in Pennsylvania showed that 30% of 128 adult 
patients was considered eligible by the providers for HCV treatment and only 
14% initiated treatment. African Americans and patients with no HCV treatment 
experience i.e. naïve had significant lower odds for treatment initiation (Cope, 
Glowa, Faulds, McMahon, & Prasad, 2016).  
In Maryland, a specialized clinic in sexually transmitted infections (STI) 
care screened 2681 patients from June 2013 to April 2014 for HCV infection. 
About 7% had HCV antibodies and 5.8% confirmed with HCV RNA. About 89% 
of the confirmed cases followed for treatment consideration, 85% were referred 
to HCV specialist, and only 52% attended their specialist appointment (Falade-
Nwulia, Mehta, et al., 2016).  
In Connecticut, a study on HIV clinic revealed that of the 135 HIV/HCV 
participants: 71% were referred for HCV treatment, 36% had full laboratory 
results and eligible for treatment, 21% received treatment prescription, and only 
13% completed treatment and achieved SVR over the period 2002-2014 (Weiss, 
2015).  
B- Affordability 
Economic Benefits of Directly Acting Antiviral Treatment 
The economic benefits from HCV treatment cannot be measured as a 
cost-benefit analysis considering only its monetary gain. A sound analysis should 
factor in the clinical benefits gained by reducing the patients suffering from the 
infection and its health consequences. Accordingly, the gold standard economic 
analysis should assess treatment costs per gained quality-adjusted life years 
(QALYs) reflecting the concept of value based medicine. Nevertheless, a cost-
effectiveness analysis interpreting the health gains from the DAAs is always 
subjected to criticized estimations. First, a widely accepted precise estimation of 
the clinical gains from the high costs of all-oral DAAs compared to the less 
expensive old IFN-based therapy is difficult. In addition, there is no consensus on 
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the societal willingness to pay (WTP) for a single QALY, a historical value of 
$50,000 has been used for decades in the United States since 1970s; however, 
a $100,000 estimate has been utilized in many calculations recently (Younossi, 
Birerdinc, et al., 2016).  
Several studies applied modelling methods to estimate the comparative 
cost-effectiveness of all-oral DAAs therapy. A study used the Quality-adjusted 
cost of care (QACC) indicator which is calculated by subtracting the increase in 
QALYs, valued at $50,000 WTP threshold, from the increase in treatment cost. 
The results showed that all-oral DAAs regimen had a $48,350 higher cost 
compared to a combined DAAs and IFN regimen. Nevertheless, the high clinical 
efficacy associated QALY gains of the all-oral DAAs regimen resulted in a 
favorable QACC of $14,120 compared to the combined therapy. This favorable 
figure increased significantly on raising the WTP threshold to $100,000 and 
$300,000 (Z. M. Younossi et al., 2016).  
Another study compared the old IFN-based therapy with all-oral DAAs 
Sofosbuvir/Ledipasvir regimen. The later regimen yielded higher outcomes by 
0.56 QALYs at a $55,400 incremental cost-effectiveness ratio (ICER) per 
additional QALY. Considering the patient previous treatment experience, liver 
disease stage, and genotype; the ICER would range from $9,700 to $284, 300 
per QALY. The same study projected that over a five-year time period the costs 
of DAAs to treat all eligible HCV infected patients in the US will be $65 billion 
higher than the costs of old IFN-based regimens; however, the cost-offset would 
reach $16 billion (Chhatwal, Kanwal, Roberts, & Dunn, 2015).  
Using the same DAAs regimen i.e. Sofosbuvir/Ledipasvir, a study took the 
comparison to the direction of estimating the differential cost-effectiveness of 
treating different stages of liver disease. The study results estimated that treating 
all stages adds 0.73 QALYs equivalent to $28 899 for an ICER of $39, 475 per 
QALY gained compared to treating advanced patients at fibrosis stages F3 and 
F4. A stepwise comparison of the four stages of fibrosis reveals that treating F3 
patients yields a 2.27 higher QALYs compared with treating patients at F4; F2 
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treatment yields 0.55 QALYs gain vs. F3 treatment, F1 yields 0.14 QALYs gain 
vs. F2 treatment, while the lowest stage of fibrosis F0 has a gain of 0.03 over F1 
stage treatment (Chahal et al., 2016).  
A long term projection estimated that the investment in oral DDAs over a 
fifty-year time period would generate additional QALYs equivalent to $610 to 
$1,221 billion and $139 medical expenditure savings on treating all patients at all 
disease stages with DAAs (Van Nuys et al., 2015). 
Hepatitis C Treatment Spending  
The total US spending on viral hepatitis treatment increased dramatically 
after the approval of the DAAs in 2014. While the last years of the IFN-based 
therapy era showed $2.1, $2.9, and $1.9 billion spending in 2011,2012, and 2013 
respectively; the spending escalated to $12.2 and $18.8 billion in 2014 and 2015 
ranking the seventh among all non-discounted drug spending in the US. 
Regarding new brands’ spending, viral hepatitis new drugs had $11.3 and $7 
billion spending in 2014 and 2015. Harvoni®, Gilead Sciences’ DAA product, 
topped the list of all non-discounted medicines in the US in 2015 with $14.3 
billion (IMS Institute for Healthcare Informatics, 2016b).  
In parallel, Medicaid spending on DAAs escalated. In 2014, 14 states’ 
Medicaid programs spent on Sovaldi® more than any other drug and 33 
programs spent on it as one of its top five pharmaceutical expenditures’ list 
(Rubin, 2016). In Medicare, Part D plans’ spending on DAAs increased from 
$283 million in 2013 to $4.5 billion in 2014, more than $3 billion were spent on 
Sovaldi® alone (Jung, Feldman, Cheong, Du, & Leslie, 2016).  
Hepatitis C Drugs Supply Chain and Payment Procedures 
The pharmaceutical supply chain of DAAs is linear and has many 
contributors. It starts with the pharmaceutical company producing the drug. 
These companies sell their products to the wholesale distributors who store 
drugs and distribute them among pharmacies and medical facilities. While large 
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hospitals and clinics, and federal medical facilities purchase their drugs from the 
wholesale distributors; chain pharmacies purchase directly from pharmaceutical 
companies and play the role of the whole sale distributer. Finally, the pharmacy 
dispenses the drug to patients and manage billing with insurers (Rosenthal & 
Graham, 2016).  
The payment pathway is more complex than the supply chain. Basically, 
there is a third party for price negotiation beside the supply chain contributors. 
This third party is the Pharmacy Benefit Managers (PBM) who negotiate prices 
for the insurers. Payment has two pathways; first, the initial payment is done in 
reverse order of the supply chain starting with the PBM who pays the pharmacy. 
Usually the initial payment is a percentage of the total payment based on its 
timing and purchase power of the payer. The second pathway is the rebate 
where the pharmaceutical companies rebate to PBMs, pharmacies, and 
government organizations. Companies formulary payments i.e. rebate to their 
PBM, are done for the later role in giving market preferences against competitors 
e.g. better copayment offers. In addition, some companies provide a market 
share rebate when the PBM succeed to entice the consumers to purchase their 
products. Other forms of rebates include volume-based discounts for achieving a 
predetermined target sale volume. Some companies encourage payers to pay 
their initial payments within earlier time period by offering prompt pay rebates 
(Rosenthal & Graham, 2016). 
Governmental healthcare bodies possess high negotiation power for their 
huge number of beneficiaries and nationwide distribution of contracted medical 
facilities. Accordingly, they gain special offers in drug prices, initial payments, 
and rebates from pharmaceutical companies to include their drugs in their 
formularies. Price negotiations revolve around average price paid by wholesale 
distributors to pharmaceutical companies i.e. Average Manufacturer Price (AMP), 
which publically unavailable (Rosenthal & Graham, 2016).  
Medicare run its drug purchase process under Medicare Part D plans. 
Private insurers or PBMs manage these plans setting the formularies, prices, and 
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discounts for Medicaid is prohibited by law from negotiating prices and receives 
the higher rebate from either a 23.1% of the AMP or the difference between the 
AMP and the best-price i.e. lowest price paid by a private payer. An equivalent 
pricing is given to the 340B pharmacies and non-federal entities servicing 
indigent populations who are covered by Medicaid (Rosenthal & Graham, 2016). 
However, states’ Medicaid plans negotiate DAAs rebates with pharmaceutical 
companies either by themselves or through a PBM resulting in different contracts 
and accordingly different access potentials for patients (Canary, Klevens, & 
Holmberg, 2015).  
The Federal Supply Schedule (FSS) manages drug pricing for the VHA, 
Federal Prisons, Public Health Services, Department of Defense, and Indian 
Health Services. These discounts offered to the FSS is higher than those offered 
by private insurers to Medicaid Part D plans. Besides, the initial price paid by the 
FSS has to be under the federal ceiling counted as the AMP minus 24 %. 
Moreover, the negotiation power of the FSS on rebates result in a final lower 
prices (Rosenthal & Graham, 2016).  
State incarceration systems don’t have negotiation powers like Medicare, 
Medicaid, and the FSS. Consequently, they pay the highest prices and contribute 
to elevating the market best-price (Rosenthal & Graham, 2016). 
Specialty pharmacies are financially incentivized by pharmaceutical 
companies, insurers, or PBMs to offer drug adherence supporting services, side 
effects management, and outcomes evaluation e.g. discontinuation and SVR 
rates (American Association for The Study of Liver Diseases, 2015).  
Directly Acting Antiviral Drugs Prices 
Pharmaceutical companies predominantly target the maximum possible 
profit from their DAA product based on market analysis considering multiple 
internal factors including: cost of research and drug development; manufacturing 
and marketing costs; novelty and effectiveness of the drug; cost-effectiveness 
and budget impact models; and shareholders expectations. External factors 
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include: prices offered by competitors; availability of generic drugs; and the 
negotiation power of different purchasers. Collectively, these factors determine 
the sticker price for the DAA which is commonly known as the Wholesale 
Acquisition Cost (WAC). This price doesn’t represent a simple targeted return on 
investment nor consider access to consumers with low payment ability 
(Rosenthal & Graham, 2016).  
The WAC of IFN-free DAA regimens timeline stared with the Gilead 
Sciences’ novel DAA Sovaldi® (Sofosbuvir) in late 2013. Sovaldi® was publically 
known as the $1,000 pill drug with a 12-week course of treatment set at WAC of 
$84,000. Harvoni® (Ledipasvir/Sofosbuvir), more effective and broadly prescribed 
Gilead Sciences’ drug, course of treatment was set at $94,500 WAC in 2014. 
AbbVie competed with its combined DAAs Viekira Pak® 
(Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir) setting a WAC at $83,319.  
Bristol-Myers Squibb produced Daklinza® (Daclatasvir) to be combined with 
Sovaldi® for a total WAC of $147,000. Merk competed with a lower WAC 
combination, Zepatier® (Grazoprevir/Elbasvir), for $54,000. Together, Harvoni® 
and Viekira Pak® possess 80 % of the current DAA market in the United states 
(Rosenthal & Graham, 2016).  
While the WAC and payment pathway are known, the final DAAs prices 
for different purchasers are not publically announced leading to non-transparent 
DAAs market (Konerman & Lok, 2016; Rosenthal & Graham, 2016). This is 
attributed to the fact that negotiations for DAAs prices are confidential business 
contracts except the FSS mandated rebates (Saag, 2015).  
Market competition and negotiating power of different purchasers played 
major role to tame the WAC overtime. In average, the estimated negotiated 
discounts on the DAAs WAC increased from 22% in 2014 to 46% in 2015 
(Wyden & Grassley, 2015). The highest estimates for Sovaldi® and Harvoni® 
discounts reached 55% in 2015 (IMS Institute for Healthcare Informatics, 2016a). 
Aggressive market competition resulted in great reduction in Gilead Sciences’ 
products final prices. To keep the company leading position, Harvoni® and 
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Sovaldi® courses’ average net prices i.e. final prices after negotiations, were as 
low as $50,400 and $44,520 respectively for a 12-week course in 2015. Based 
on these prices and an estimated 236,874 patients treated with these two drugs 
in 2015, the total net spending on standard courses using Harvoni® and Sovaldi® 
was $10.9 billion (IMS Institute for Healthcare Informatics, 2016a). This net total 
is way less than the estimated 2015 $14.3 billion spending on Harvoni® alone; 
however, the difference might be attributed to other costs of HCV services beside 
the drug cost (IMS Institute for Healthcare Informatics, 2016b).   
A retrospective cohort study conducted at a VHA medical center between 
October 2014 and September 2015 found that the average DAAs spending to 
cure was $40,135 per patient. Cirrhotic patients’ DAAs spending to cure was 
higher ($41,907) than non-cirrhotic patients ($38,431), and treatment-
experienced patients had higher spending to cure ($39,482) compared to naïve 
patients ($39,179) (Yang, Britt, Hashem, & Brown, 2017).  
In addition to the type of insurance coverage and final price ambiguity, 
other factors affect the direct cost burden on patients. Pharmacy plans apply 
copayment plans on patients for the DAAs; however, the patient assistance 
programs may cover part or all copayments for different patients according to 
their ability to pay (Saag, 2015). In 2015, the mean out-of-pocket spending on 
DAAs ranged from $6,297 to $10,889 for Medicare Part D plans beneficiaries 
with no subsidy. Low-income subsidy group spent significantly lower out-of-
pocket expenditure between $10.80 and $1,191 (Jung et al., 2016).  
One of the major consequences of DAAs pricing complexities is the 
limitations on patients’ options for DAAs choice due to the exclusive deals 
between their insurers and pharmaceutical companies. The majority of the 
current exclusive deals aiming at cost reduction are done with Gilead Sciences 
for Harvoni®, few are with AbbVie for Viekira Pak ®, and only one reported deal 
with both companies (Wittkop, Rosenberg, Garfield, & Greenwald, 2015).   
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Distribution of Hepatitis C Patients Among Different Insurers 
Two decades before the approval of the DAAs, NHANES data from 1988 
to 1994 revealed that 29.6% of HCV infected Americans had no insurance 
coverage while less than half this percent (12.2%) of non-infected citizens are 
uninsured (McGowan & Fried, 2012).  
Recently, it is estimated that 86.9% of HCV infected Americans who are 
aware of their status are insured while only 60.4% of unaware infected persons 
are insured (Yehia et al., 2014). Another study followed identified HCV positive 
patients by the NHANES from 2001 to 2010 revealed that 19.4% attributed their 
failure to initiate the treatment to its high costs. Besides, the only significant 
independent variable for treatment was lack of health insurance coverage (Ditah 
et al., 2015).  
An analysis of NHANES data to quantify the distribution of confirmed HCV 
RNA positive patients according to their affiliation to different health insurers in 
2013 showed that the uninsured patients comprised the highest portion 
(1,012,000 patients) followed by those under the coverage of private insurers 
(779,000 patients), incarceration system (450,000 patients), Medicaid (377,000 
patients), VHA (302,000 patients), both Medicaid and Medicare (201,000 
patients), Medicare (117,000 patients), and other military coverage (10,000 
patients) (Bruce Pyenson & Engel, 2013). Another study estimated that of the 68 
million Medicaid enrollees in 44 states, about 700,000 have positive antibodies to 
HCV (Wyden & Grassley, 2015).  
In 2015, the estimated proportion of HCV infected patients under private 
insurance coverage was 38% followed by 24% Medicare, 13% Medicaid, 6% 
other public insurance, and 19% uninsured (Chhatwal et al., 2016). 
The 2013 NHANES analysis pointed to the shift of HCV patients towards 
Medicare overtime. The distribution of HCV RNA prevalence by year of birth from 
1910 to 2010 pointed to the fact that the high prevalence of HCV among baby 
boomers will result in their inclusion under Medicare, by the age rule, when they 
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turn 65 between 2010-2030. Given the natural history of HCV infection 
progression towards liver affection, a young patient at the time of contacting the 
infection would probably fall under Medicare coverage in advanced stage of liver 
disease (Bruce Pyenson & Engel, 2013). In the same direction, another study 
claimed that this aging phenomenon resulted in increasing Medicare HCV 
infected enrollees from 18% in 2010 to 24% in 2015. Besides, the Affordable 
Care Act (ACA) shifted the uninsured HCV infected patients from 26% down to 
19% yet these uninsured patients are the least enabled group to access 
treatment and consequently would comprise the highest proportion of HCV 
patients by 2019 (Chhatwal et al., 2016). 
Different Insurers’ Approval Criteria and Barriers for the Directly Acting 
Antiviral Treatment 
1- Commercial Insurance 
As the ACA prohibited refusal of coverage for preexisting health 
conditions; private insurers may fear adverse selection where HCV patients opt 
for enrollment in the generous plans rather than the stricter ones. Consequently, 
private insurers would be reluctant in covering the costly DAAs in their plans. The 
National Academies of Sciences, Engineering, and Medicine 2016 report 
“Eliminating the public health problem of hepatitis B and C in the United States: 
Phase one report” underscored this dilemma as a threat for private insurance 
market failure in HCV treatment (National Academy of Sciences, 2016).  
Additionally, the ACA out-of-pocket (OOP) expenses limits in 2016 were 
$6,850 for individuals and $13,700 for families hindering the HCV patients from 
DAAs costly treatment (Rodriguez & Reynolds, 2016). 
Commercial health insurers are steadily shifting the costs of specialty 
drugs and costly healthcare costs including DAAs services to their beneficiaries 
under different titles: premiums, deductibles, co-payments, and co-insurance 
(Spiro, Calsyn, & O’Toole, 2015). With these cost-sharing variations and titles, 
DAAs are unequally offered across private insurers’ plans (Rodriguez & 
41 
 
Reynolds, 2016). Moreover, the DAAs are classified as specialty drugs and often 
placed among the drug formulary high cost-sharing tier. In 2015, more than 25% 
of Silver plans nationwide placed DAAs on specialty tiers (Pearson, 2015). In 
Massachusetts, two commercial insurance plans who applied adverse tiring to 
DAAs revealed that more than half of two plans, Silver and regular, placed DAAs 
either at the highest rank formulary tiers or didn’t cover them (Wittkop et al., 
2015).  
2- Medicare Program 
Medicare DAAs coverage is provided under Medicare Part D. To have 
DAAs covered, patients need to be enrolled in prescription drug plan covered by 
a private insurer. The two pathways for prescription coverage are: Medicare 
Prescription Drug Plan beside the original plan or a Medicare Advantage 
Prescription Drug plan. In reality, most Medicare patients have these prescription 
coverages and are able to initiate DAAs therapy once their clinical provider 
complete their assessment (Cross, 2016; Rosenthal & Graham, 2016).   
3- Medicaid Programs 
State Medicaid programs cover the majority of HCV patients in need for 
DAAs; however, they apply the most restrictive approval criteria among insurers. 
These approval criteria are applied in the “Prior Authorization (PA)” approval. The 
pharmacy or prescribing clinician have to submit a request documenting that the 
patient is compliant with the required criteria. The insurer either accept or deny 
the request and in case of denial, an appeal can be filed by the request provider. 
This process is complex both clinically and administratively and requires time 
(National Academy of Sciences, 2016).  
The PA criteria are inconsistent among Medicaid programs and may 
include: 
Proof of Advanced Liver Disease. Approval criteria for most Medicaid 
program target the AASLD ranked “highest priority” patients while neglecting all 
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other high priority patients in need. These restrictive criteria are applied in 33 
states and require an evidence of advanced liver disease attested by a METAVIR 
fibrosis score of F3 or F4 for Sovaldi® approval. Moreover, 4 states require an 
invasive liver biopsy rather than imaging and laboratory investigations (Canary et 
al., 2015). About 81% of Medicaid programs apply this role in general terms i.e. 
evidence of advanced fibrosis and 74% accept only METAVIR fibrosis score of 
F3 or above (Barua et al., 2015).  
The Sobriety Role. Most Medicaid programs (88%) require abstaining 
from substance abuse i.e. illicit drug use and/or alcohol for a period ranging from 
3 to 12 months. The argument behind this role is to ensure success of treatment 
and to avoid reinfection. For complying to this role, patients in 64% of programs 
have to undergo drug screening either before or periodically during treatment, 
and in some programs complete substance abuse treatment program or join an 
addiction counselling program with a specialist is also required (Barua et al., 
2015; Wittkop et al., 2015).  
Provider Restrictions. About 69% of Medicaid programs requires a 
specialist to prescribe or at least be consulted in DAAs regimens. This 
requirement challenges many patients in underserved areas lacking specialist 
services (Barua et al., 2015).  
Special Treatment for HIV/HCV Patients. About one quarter (24%) of 
Medicaid programs require HIV/HCV patients to be engaged in HIV ART or 
provide and evidence of HIV RNA suppression (Barua et al., 2015).  
Facing these restrictions, the Center for Medicare and Medicaid Services 
(CMS) published a guidance report in November 2015 to encourage and remind 
state Medicaid programs of their legal responsibility toward HCV patients. 
Basically, the report pointed out that Medicaid programs’ cost containment 
strategies restricting HCV effective treatment are against the federal law. In this 
report, “Assuring Medicaid Beneficiaries Access to Hepatitis C Drugs”, the CMS 
underscored three elements coupled opportunities for feasible implementation 
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mechanisms. First, the DAAs are both necessary and effective giving no other 
option neither for the patients nor their insurance. As a reminder and key 
solution, Medicaid managed care programs enrollees should benefit from the 
DAAs covered in approved state plans. The second key element in the CMS 
report highlighted the mechanisms that can help reduce DAAs cost via either 
including them in the managed care contracts or apply capitation rates or carve-
out supplementary plans. Third, the CMS pointed to the importance of the 
opportunity resulting from the competition among pharmaceutical companies in 
reducing the DAAs prices and offering better rebates for Medicaid programs 
(Centers for Medicare & Medicaid Services, 2015). 
The National Academies of Sciences, Engineering, and Medicine 2016 
report offered a benchmarking solution that can help leverage access to DAAs 
through delegation of the federal government to negotiate discounts for low-
income patients reference to the Vaccines for Children program (National 
Academy of Sciences, 2016).  
Medicaid Prior Authorization Approval Rates 
A study investigated the PA approval rates and predictors among 
Massachusetts Medicaid program during the following year after the approval for 
Sofosbuvir® in December 2013 revealed that about 5% of patients had a PA 
request and 90% of them were given the PA. About 71% of approved patients’ 
request were for all-oral DAAs while the remaining proportion was for combined 
IFN and DAAs regimens. Each of the infectious diseases (ID) and 
gastroenterology specialists’ groups requested 37% of the approved PAs. 
Hepatologists requested 21%, and internal and family medicine practitioners 
requested 4% of the PAs. PA requests were higher among Caucasians, males, 
those aged between 50 and 64 years, the disabled, those having the standard 
Medicaid plan, and those in advanced stage of liver disease. Lower percentages 
of PA requests were associated with homelessness, drug abuse, and primary 
care community health center engagement. The most common PA disapproval 
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reason was lacking complete information required from the provider (Clements et 
al., 2016).  
Another study explored the distribution and predictors among a sample of 
privately insured patients nationwide who had PA request between March and 
June 2014. In this study, 59.4% of the PA requests were for IFN-free regimens 
and 90% of PA requests came from either a gastroenterology or hepatology 
specialist. The distribution of patients showed that 61% were males, mean age 
was 55.4 years, and their geographical distribution was as follows: 38.2% from 
southern states, 21% from northeastern states, 20.4% from western states, and 
20.4% from Midwestern states (Tambourine et al., 2016).  
At Yale University Liver Center, a study examined the PA rates for 
Harvoni® during October-December 2014 found a 91.4% total PA rate (77.5% PA 
rate without appeal and 13.9% after the first appeal). The average time to PA 
was 22.9 (SD ± 21.2) days. Significant independent predictors for approval were 
public insurance i.e. Medicare or Medicaid, and HCV RNA load over 6 million 
IU/mL (Do et al., 2015).  
A study on University of California Los Angeles all payer HCV treatment 
services between October 2014 and July 2015 revealed a total 81% PA approval 
rate were distributed among public (63.7%) and private (36.7%) pharmacies. PA 
approval was given to 75.6% of approved PAs without appeal, 10.4% after the 
first appeal, and 1.2% after the second appeal. The mean time from PA request 
submission to drug approval was 28.1 (± 46) days. According to type of 
insurance, Medicare patients had the highest approval rate (92%), followed by 
Medicaid patients (80%), non-Medicaid health maintenance organizations 
patients (78%), and private insurance patients (70%). Higher approval rates were 
among males (58.1%), middle-income group (67.1%), advanced liver condition 
(51%), and employed (43.1%) patients. Adjusted significant independent 
predictors included Medicare insurance, advanced liver disease, and lack of 
other comorbidities (Saab et al., 2016).  
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A four-state study conducted on a specialty pharmacy chain database 
found 16.2% PA denial rate between November 2014 and April 2015. The most 
common reasons for denial included lack of sufficient information supporting 
medical need (35.5%), lack of medical necessity (35%), failure in drug screening 
test (4%), and prescription of a non-preferred DAA by the pharmacy (2.7%). 
Among Medicaid patients, 46.3% received denial while 10.2% of privately insured 
and 5% of Medicare patients were denied. Adjusted variables significantly 
associated with PA denial included Medicaid insurance and non-advanced liver 
disease identified by absence of cirrhosis (Lo Re et al., 2016).  
A single center study in Michigan found that between December 2013 and 
May 2014 the PA approval rate for the combination Simeprevir (Olysio®) 
and Sofosbuvir (Sovaldi®) was 67.7% (George, Weick, Moonka, Segovia, & Jafri, 
2014).  
Cost-Value for Medicaid Expansion of Approval Criteria 
Several studies proved the cost-effectiveness of full-access to DAAs for 
Medicaid beneficiaries. A study compared the cost-effectiveness of restricted 
versus full-access policies Medicaid policies on beneficiaries aged 40-55 
revealed that the currently applied restrictive policy is costlier by $9,200 per 
patient with 0.84 lower QALYs. In addition, the full-access policy is estimated to 
prevent 5,994 HCC cases and 121 liver transplants per 100,000 patients. On the 
long term, the study projected a cost saving exceeding $3.5 billion for the 
estimated 450, 000 HCV Medicaid patients if the full-access policy replaced the 
current restrictive policy (Chidi et al., 2016). Another study projected additional 
0.84 life-years per patient and prevention of 36,752 cirrhotic cases; 1,739 liver 
transplants; 8169 HCC cases; and 16,173 HCV-related deaths per patient in 
case of providing Harvoni® to all patients compared to treating advanced liver 
disease patients only with the same drug. The cost saving according to his study 
scenario is expected to reach $3.8 (Zobair Younossi et al., 2017). Considering 
the additional burden of high risk groups, a study factored in treating PWIDs, 
men having six with men, and HIV co-infected patient in estimating the cost-
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effectiveness of the full-access scenario. Treatment expansion including all types 
of patients at all stages would reduce new infections by more than half (55%) and 
prevalence by 93% over two decades. Moreover, it will add 1.15 QALYs with 
$1,626 reduction of costs per patient over the same time frame. Considering a 
$150,000 WTP value, the net social benefits would reach $500 billion over two 
decades (Moreno et al., 2017). 
Denied Medicaid beneficiaries are expected to fall under Medicare in the 
future with probably full coverage of HCV treatment including DAAs and liver 
disease complications. Based on this inevitable scenario, a study estimated the 
cost reduction of treating Medicaid patients on future Medicaid expenses in 
Pennsylvania. First, the study estimated that Medicaid expansion of treatment to 
include one more fibrosis stage i.e. Metavir F2 score patients, this limited 
expansion would add $273 Medicaid spending over a decade with limited effect 
on liver disease morbidity but a reduction of the expected costs of treatment 
under Medicare by 10%. Full-access scenario including all patients would cost 
Medicaid additional $693 million over the same time period; however, it would 
reduce the future patients in need for treatment under Medicare coverage by 
46% and consequently the costs by 23% plus significant reduction of morbidities 
(Kabiri et al., 2016).  
C- Geographical Accessibility 
Services Locations and Patients Distance from Different Providers 
Unequal distribution of HCV treatment centers and specialists is one of the 
major obstacles for DAAs mass provision and elimination of the disease. The 
CDC recognizes this obstacle and supports training of primary care providers in 
remote and rural areas to overcome the geographical accessibility barrier to 
specialized HCV services (M. Klevens et al., 2014).  
A study conducted by the CDC to explore the distance of HCV patients 
from different providers ordering HCV laboratory tests showed that the patient to 
provider median distance was 12.1 miles. The shortest median distance was to 
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primary care providers: internal medicine specialists (8 miles), general 
practitioners (10 miles), and family medicine practitioners (11.5 miles). HCV 
specialists had the highest distance from patients; the hepatoligists median 
distance was 22.7 miles and for the gastroenterologists it was 12.4 miles (M. 
Klevens et al., 2014).  
Another study compared the major barriers from the patient side after 
referral for HCV treatment at a centralized academic medical center with a 
community based clinic in North Carolina. Results revealed that the only 
significantly different barrier between the two clinics was the distance. Nearly 
40% of the academic medical center patients identified distance as a problematic 
barrier compared to 17% of the community based clinic patients (Evon et al., 
2010). 
D- Acceptance 
Stigma 
HCV stigma is rooted in the association of the infection with substance 
abuse and HIV. Stigmatization and social rejection are identified major barriers to 
accessing HCV care in almost all contexts. Stigmatizing HCV patients is not 
limited to society but extends to healthcare settings. When patients feel 
stigmatized by their providers, they lose interest in follow-up and their probability 
to initiate and adhere to providers’ recommendation falls down significantly (Evon 
et al., 2010; McGowan & Fried, 2012).  
Providers’ Attitudes  
Providers’ negative attitudes towards PWIDs represent a critical bias in 
HCV treatment. These attitudes are associated with providers’ mistrust in PWIDs 
adherence to treatment plans, fear of possibility of reinfection, and negative 
perception about psychological problems rendering them difficult to treat patients 
(Zeremski et al., 2013).  
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A survey conducted among HCV treatment prescribing clinicians in 2014 
showed that only 52% were willing to treat abstaining PWIDs for 6 months or 
more, 35% for 1-6 months abstaining period, and 15% were willing to treat HCV 
patients who are active drug users i.e. had an injection within the prior 30 days. 
The odds of willingness to treat PWIDs increased proportionally with abstinence 
period. The odds ratio for 1-6 abstinence period was 4.8, 17.1 for 6-12 months, 
and 17.5 for 12 or more months (Asher et al., 2016).  
Trust in providers’ competences is another barrier to HCV treatment. A 
study identified lack of trust in providers’ competence as a perceived barrier by 
HCV patients hindering treatment initiation and adherence (Evon et al., 2010).  
Cultural Acceptance 
There is a paucity of studies conducted on cultural acceptance of all-oral 
DAA therapy; however, it is anticipated that oral therapy is convenient for most of 
population groups. Nevertheless, cultural acceptance is closely tied to awareness 
among the community about the efficacy and tolerance of DAAs.    
Patient Education 
Patients’ limited awareness and misunderstandings about the DAAs 
treatment encounters most of the patient side barriers to treatment initiation and 
adherence (Grebely, Oser, Taylor, & Dore, 2013). Treatment fears have been 
identified major factors since the IFN-based therapy era, these fears revolve 
around treatment efficacy and side effects (McGowan & Fried, 2012). It is 
estimated that 65-75% of HCV-infected PWID are neither aware of their infection 
nor aware of the effectiveness of DAAs in HCV cure (Zeremski et al., 2013) 
A study explored the motivating and hindering factors for patients to 
initiate and adhere to HCV treatment showed that most salient motivating factors 
for patients in order are: fear of negative health outcomes of HCV, patient’s 
personal will, provider’s advice, fear of HCV impact of quality of life and achieving 
future life goals, and receiving laboratory results and success likelihood of 
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treatment. Major hindering factors were nonspecific side effect and possible need 
for injection therapy (Fusfeld et al., 2013). 
Reassurance and proper awareness about the current all-oral regimens 
are mandatory to resolve this problem. Consequently, patient education is very 
crucial to help patients initiate treatment and ensure adherence to treatment 
plans. Prior to DAAs, the liver specialty clinic of San Francisco’s safety net 
healthcare system in California mandated a formal HCV education class to all 
HCV patients referred to the clinic before evaluation for treatment. The education 
curriculum was delivered by specialized nurse practitioner in a two-hour 
presentation in English with availability of interpreter for other languages when 
needed. The content of this presentation included information on HCV 
transmission, diagnosis, symptoms, natural history, impact on liver, eligibility for 
treatment, treatment response rates, and potential adverse effects of treatment. 
Outcomes of this education program showed significantly shorter time to 
treatment initiation compared to patients who didn’t join the program. Positive 
provider attitude was significantly associated with the referral rate to the program. 
About 70% of specialists reported increase knowledge among patients after the 
program, 52% reported increased interest in treatment, and 56% acknowledged 
improved communication with patients (Lubega, Agbim, Surjadi, Mahoney, & 
Khalili, 2013).  
E- Accommodation 
Linkage to Care  
The national viral hepatitis action plan 2017-2020 recommends 
mainstreaming of HCV screening and linkage to care as standard practices in the 
healthcare settings (DeSalvo et al., 2017). The primary point of care and the 
fostering healthcare setting for patients are diverse. For instance, PWID start 
their healthcare navigation through urgent and emergency services. Accordingly, 
the American College of Preventive Medicine recommends linkage to HCV 
testing and treatment through utilization of all possible facilities including federally 
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qualified health centers, patient centered medical homes, inpatient settings, and 
emergency departments (Allison et al., 2016).  
In 2012, the Congress allocated funds to the CDC toward improving viral 
hepatitis testing and linkage to care. Accordingly, the CDC launched the Hepatitis 
Testing and Linkage to Care (HepTLC) initiative that provided 25 grants to HCV 
focused heath organizations. Components of this initiative included HCV services 
in community health centers, testing in PWID settings, and both testing and 
linkage to care in other settings. Between September 2012 and September 2014, 
the initiative tested 57,570 participants for HCV antibodies in 15 states and 
districts, 4,765 were tested for HCV RNA, 3,449 were confirmed with chronic 
infection. Out of 2,798 received2,624 were referred to specialty care and 1,509 
made a visit to HCV specialist. Results showed that the maximum benefit of 
linkage to a one-facility comprehensive care was among homeless PWIDs 
(Ramirez et al., 2016).  
Beside these regular settings, mobile clinics can be a standardized 
starting point for linking HCV patients to care especially in high prevalence 
underserved remote areas. In Connecticut, a mobile clinic-based program from 
2012 to 2013, included HCV screening in routine health assessment. The 
program offered two HCV testing choices for participants: rapid onsite test and 
regular laboratory-based tests. Identified HCV-infected participants were linked to 
care by the program.  Results showed that HCV patients who opted for rapid 
testing were more likely to be linked to HCV treatment (Morano et al., 2014). 
Patient Navigators 
Patient navigation is a supportive intervention using community healthcare 
workers or social workers to support continuity of care. Navigators help 
overcome the healthcare system barriers hindering effective access to prevention 
and treatment services especially among: difficult to reach populations for a 
stigmatized risky behavior, disadvantaged underservices populations in 
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geographically remote areas , and those unaware of their status or how to 
approach curative treatment (Ford, Johnson, Desai, Rude, & Laraque, 2016).  
The CDC fostered HepTLC initiative is following the patient navigator 
model. The initiative results revealed that counselors and patient navigators 
ensured adherence to medical appointments through awareness and facilitating 
transportation. Besides, navigators from the patients’ local community who speak 
the same language could deliver culturally accepted health awareness and 
linkage to care message (Ramirez et al., 2016).  
At state level, the New York City Department of Health and Mental 
Hygiene have implemented, with private sector fund, its patient navigation 
program “Check HepC” since 2012. Under supervision of an onsite-supervisor, 
four navigators were recruited over two years, two of them were fluent in 
Spanish. Each navigator worked closely with a multidisciplinary team either in on-
site clinical care facilities or off-site substance abuse harm reduction settings. 
The navigators’ tasks started with comprehensive assessment of patients’ needs 
followed by developing an individualized care plan for each patient. Navigators 
provided education messages, counselling, insurance and PA approval and 
appeal support. The treatment initiation rate among Check HepC patients 
reached 33% from March 2014 through January 2015. On-site patients showed 
higher odd of treatment initiation compared to their off-site counterparts (Ford et 
al., 2016).  
One of the pioneer HCV patient navigation interventions have been 
conducted in Pennsylvania and showed successful results in facilitating access 
from testing to cure with support from both patient navigators and clinical social 
worker. This community-based intervention reached out to 1,301 random 
participants via mobile clinics from February 2012 to February 2014 and could 
identify 52 participants with HCV antibodies. The program navigators succeeded 
to identify HCV antibody carriers, conduct confirmatory HCV RNA testing, and 
link chronically infected patients to specialized HCV services. Patient navigators 
reached patients for follow-up by phone and home visits to non-respondents. To 
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achieve linkage to care, the navigators could help enroll the uninsured Medicaid 
eligible patients and link them to a primary provider through the program support. 
Once the patient had insurance coverage and a primary provider, navigators 
supported patients in getting referral to HCV specialist either through illustrating 
the process, reminding patients to contact their primary providers, or requesting 
in person the referral on behalf of the patient (Trooskin et al., 2015).  
In North Carolina, an interventional study from December 2012 to 
February 2014 used counselors as patient navigators to provide post-test 
counseling beside linkage to care. The counselors either reached out to patients 
through phone calls, in person meetings, and community visits. Moreover, the 
interventional study let the HCV specialists provide medical assessment and 
follow-ups to patients in substance abuse services facilities and health 
departments to ensure patients adherence. Incarcerated patients were included 
in the intervention as well, either linked to care after release or referred within the 
incarceration healthcare system. The overall linkage to care rate of the study 
reached 51% (Seña et al., 2016).  
In 2014, a pilot patient navigation program in Chicago, Illinoi identified 
three major healthcare barriers to HCV treatment in HIV co-infected patients: low 
rate of HCV confirmatory tests, referral to specialists for evaluation, and PA 
processing capacities. Individual barriers according to the study are substance 
abuse, mental health problems, and lack of permanent housing. The study 
navigators commenced their work with patients’ needs assessment, and 
connection to HCV treatment facilities in addition to substance abuse and mental 
health providers. The program succeeded to increase confirmatory testing rate 
from 50% to 100%. Referral rate was 67.5%, PA requests were sent for 23.9% of 
patients and 19.6% initiated treatment (Glick, Armstrong, Tobin, & Allgood, 
2016).  
To compare the cost-effectiveness of different linkage to care models, a 
study simulated four hypothetical intervention strategies in DAAs therapy: linkage 
to care through five visits to a case manager over three months; treatment 
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initiation through visits to a physician, nurse, and a case manager over three 
months after referral to treatment; integrated case management through visits to 
a case manager over six months to pursue the first two interventions steps i.e. 
linkage to care and treatment initiation; and peer navigator intervention through 
hand in hand peer support over twelve to eighteen months from HCV discovery 
to treatment completion. The peer navigator intervention showed the best ICER 
among all interventions ($16,200 per QALY reference to standard of care), a 
22.49 years’ life expectancy, 11.32 QALYs, and $207,300 reduction in life time 
medical costs (Linas et al., 2014).  
Integration of Care 
Given the syndemic of HCV, HIV, and substance abuse; care for these 
related health problems requires synchronized services’ provision. A 
multidisciplinary team of healthcare workers involved in management of these 
three problems is fundamental to care coordination and better clinical outcomes. 
This team should ultimately include clinical providers trained in co-management 
of HIV/HCV, substance abuse counselors, mental health specialists, case 
managers, and community health workers (Reece et al., 2014). Peer support has 
been proved efficient in improving access to HCV treatment in high risk group 
and could be integrated within the multidisciplinary team. The hosting healthcare 
setting for multidisciplinary services can be a community based primary care 
center, a substance abuse therapy center, or a specialized hospital based 
outpatient clinic (Bruggmann & Litwin, 2013).  
The national viral hepatitis action plan 2017-2020 emphasized the 
importance of integration of care for effective prevention of infection, early 
identification of HCV, and linkage to specialized care. According to the action 
plan, care coordination should engage primary and specialized clinical care, 
public health programs, mental healthcare, and substance abuse and risk 
reduction e.g. syringe exchange services. In parallel, integration should involve 
all health problems having blood-borne or sexual transmission linked risky 
behavior i.e. HIV and HBV.  Accordingly, these health problems related 
54 
 
behaviors should be under one umbrella of assessment and activities including 
counseling and education; vaccination against HAV and HBV; testing for HIV, 
HBV, and HCV; and linkage to treatment. To ensure quality improvement, 
integrated services should develop and utilize best practices in integrated models 
of care and apply a comprehensive clinical monitoring process to should guide 
these activities (DeSalvo et al., 2017).  
The US Department of Health and Human Services (HHS) action plan for 
the prevention, care and treatment of viral hepatitis fostered a similar integration 
of care model especially for high risk patients with HIV or practicing injection drug 
use. The HHS plan called for integrating HCV testing and treatment within 
substance abuse and HIV programs in addition to management of other 
comorbidities (US Department of Health and Human Services, 2011). This 
integrated care model avoids the limitations of isolated vertical programs e.g. 
financial shortage and limited time frame of funding. Besides, integration of care 
matches the holistic approach to health which helps DAAs providers manage 
their patients comprehensively especially for patients residing in rural and low-
resource settings (DeSalvo et al., 2017).  
The American College of Preventive Medicine echoed the national action 
plan and called for integration of behavioral counseling before and during DAAs 
therapy. In addition, counsellors should advocate for patients and assist with 
linking them to DAA treatment (Allison et al., 2016).  
An expert view calls for organizing partnerships at all levels between HCV 
and substance abuse services’ providers for co-provision of prevention, 
screening, and curative services (Edlin, 2016). To implement this partnership, a 
multidisciplinary care team should be established and substance abuse and HCV 
services should be co-localized. In accordance, HCV-infected patients will be 
easily identified and linked to onsite comprehensive HCV services or offsite 
specialty services (Zeremski et al., 2013). In contrast to this opportunity, the 
National Drug Abuse Treatment Clinical Trials Network found a significantly 
unconnected substance abuse and HCV testing, counseling, and treatment 
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services either in a comprehensive single facility or through referrals to 
specialized HCV facility (Bini et al., 2012).   
In Connecticut, a comprehensive onsite treatment program (OTP) for 
substance abuse included HCV testing and linkage to care within its services. 
Confirmed HCV cases were offered support from a social worker and a 
psychiatrist t for counselling and arrangement of HCV evaluation concurrently 
with substance abuse treatment. The OTP program multidisciplinary primary care 
team included two primary care physicians with HCV treatment experience 
managed the HCV patients and provided guidance to the program. In addition, 
the program offered an optional family member involvement and close contacts 
screening for identified patients (Butner et al., 2017).  
In New Jersey, a substance abuse facility institutionalized HIV, HCV, and 
HBV screening for all opioid abuse patients. Identified HCV infected patients 
were evaluated, counseled on treatment, and referred to proximal HCV providers 
to their homes. Outcomes from October 2014 to June 2015 showed that 8.6% 
could follow-up with an HCV treatment provider and 1.6% initiated treatment 
(Akyar et al., 2016).  
Multiple evidences from studies in the US, and other regions of the world, 
underscored that integration of care should include other social services based 
on the patient needs. The intensive case management model showed successful 
results in prevention and treatment of HIV and HCV as well but with limited 
applications. This model is more applicable to PWIDs with special healthcare 
needs including health insurance coverage, substance abuse and other 
comorbidities management; and socioeconomic needs e.g. housing (Meyer et al., 
2015).  
Task shifting 
According to the World Health Organization (WHO), task shifting is 
defined as a “process whereby specific tasks are moved, where appropriate, to 
health workers with shorter training and fewer qualifications” (World Health 
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Orgnaization, 2011). Applications of task shifting have been recognized by the 
WHO in HIV care for its lower costs and comparable efficiency to specialty care 
(Mdege, Chindove, & Ali, 2013).  
The successful adoption of HIV care task shifting enticed the HCV field to 
replicate this model. Task shifting in HCV is based on shifting HCV care delivery 
from centralized tertiary services to accessible community-based primary care 
providers with technical support from specialists. The quality and effectiveness of 
task shifting in HIV were comparable between the two providers even in low 
resource primary care settings. In addition, HCV management task shifting is 
privileged over HIV by the natural history of the disease and the DAAs 
availability. First, the effectiveness of DAAs and shorter treatment duration in 
HCV ensure success and rapid patient turn. Second, HCV management 
especially at early stages of liver affection needs less intensive monitoring and 
consequently less need for advanced training for the primary providers and lower 
opportunity cost from their dedicated time to HCV management. Third, 
adherence rates are accepted to be higher for HCV DAAs due to lower adverse 
effects compared to HIV treatment. Fourth, the administration of a simple all-oral 
DAAs doesn’t require highly developed infrastructure nor modification for the 
existing primary care settings (Jayasekera, Arora, & Ahmed, 2016). Maximum 
benefit from HCV management task shifting can be achieved from delegation of 
primary providers who provide substance abuse services to HCV high risk 
population (Pawlotsky, Feld, Zeuzem, & Hoofnagle, 2015).  
Preparedness and acceptance for task shifting among different types of 
providers is a key determinant for success of this model of care. A survey 
conducted among specialists and primary providers showed that referral is a 
barrier to DAAs effective management. About 77% of primary providers 
acknowledged loss of follow up of 24% of their referred patients to specialists, 
and 73% of specialists reported loss of follow up after the first visit and 15% non-
adherence to the full treatment plan. Task shifting to primary providers was 
widely accepted by both types of providers and Managed Care Organizations’ 
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pharmacy and medical directors. More than 73% of primary providers showed 
comfort with following the AASLD guidelines for HCV prescription and follow-up. 
On the other side, 98% of HCV specialists and 63% of Managed Care 
Organizations’ pharmacy and medical directors agreed that primary provider 
could efficiently prescribe HCV treatment following the AASLD guidelines 
(Levine-Wilkinson, Cummings, & Holman, 2014).  
In Maryland, primary providers were surveyed and 12% reported treating 
HCV patients in the prior year. Basically, only 22% of respondents agreed that 
HCV treatment can be delivered by primary providers; however, 84% showed 
interest in HCV training. Interestingly, willingness to provide HCV treatment 
among providers was significantly associated with higher HCV patient interaction 
and availability of closely related services to HCV high risk patients including HIV 
treatment, and substance abuse and mental health services (Falade-Nwulia, 
McAdams-Mahmoud, et al., 2016). In Michigan, a survey showed only 9% of 
primary providers were comfortable with treating HCV patients (Thomson, 
Konerman, Choxi, & Lok, 2016).  
Based on the success of the task shifting model, the integration of care 
strategy proposed by the national viral hepatitis action plan 2017-2020 
recommended capacity development of primary care providers not only for 
screening and counseling but also to treatment of HCV patients. The action plan 
called for digital collaboration in training and technical assistance between 
specialists and primary providers in remote areas to enable these providers to 
deliver comprehensive care to HCV patients (DeSalvo et al., 2017).  
The Infectious Diseases Society of America (IDSA) published a special 
position statement supporting the use of telehealth for timely, cost-effective 
specialty services in remote low-resource settings. The major concerns of IDSA 
revolve around ethical considerations in data management, licensure, and quality 
of services (Siddiqui et al., 2017).  
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In the same line with this guidance, the University of New Mexico medical 
center fostered the Project ECHO (Extension for Community Healthcare 
Outcomes) since 2003 to develop the capacities of primary providers in remote 
areas to manage underserved HCV patients. The training components of Project 
ECHO are; virtual learning platform using videoconference technology; and case-
based learning. Training has been provided by the university medical center 
specialists to primary care providers in remote areas. In addition, mutual learning 
components of Project ECHO are: sharing best practices; and outcomes 
measurement. Project ECHO basic team is multidisciplinary including a 
physician; a nurse practitioner or a physician assistant; plus a nurse or a medical 
assistant; however, with the expansion of the project all types of health workers 
have been engaged. Moreover, Project ECHO provides a real-time 
multidisciplinary team medical assessment using videoconferencing to overcome 
the time and distance barriers for patients (Thornton et al., 2016).   
Expansion of Project ECHO has been maximized at state, national, and 
international levels. At state level, Project ECHO have been collaborating with 
the New Mexico Corrections Department and the U.S. Indian Health Services 
(Thornton et al., 2016). Following New Mexico, several states have been 
applying the project for capacity development of primary providers to manage 
HCV cases. In Utah and Arizona, Project ECHO commenced in 2012 with 
support from the CDC and showed similar successful results to the original 
project (Mitruka et al., 2014). Since its establishment till 2016, Project ECHO 
provided care to more than 9,000 HCV patients (Thornton et al., 2016).  
Models for reaching patients with specialists at community primary care 
settings showed promising results as well. An intervention applied a full-day 
outreach hepatology clinics in underserved areas primary care settings in 
California coupled with telephone based follow-up by a trained nurse and 
supportive medical assistant. Specialists followed the laboratory results and 
adverse effects remotely using supportive electronic health record system. 
Patients were able to reach out the specialist and the nurse via phone and 
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secure messaging through an electronic health record system. Results showed 
high adherence and cost-effectiveness (Jayasekera et al., 2017).  
Administrative Facilitators 
Health Information Management. The national viral hepatitis action plan 
2017-2020 recommends developing a unified health record guidance associated 
with quality improvement activities to increase healthcare providers’ awareness 
of HCV testing and treatment recommendations for special patient groups e.g. 
PLWHIV. Additionally, health records should help improve screening and referral 
to DAAs based treatment (DeSalvo et al., 2017).  
Data linkage can support identification of patients and help insure 
continuity of care. A study in Wisconsin investigated HCV care continuum till 
treatment initiation in PWIDs using three data sources: syringe exchange 
program surveillance data, the HepNet C survey results, and follow-up in person 
interviews. Results showed high degree of variability among these sources for 
HCV care continuum (Hochstatter et al., 2017).  
Prior Authorization Support. To facilitate and speed up the PA process 
a study recruited three pharmacy students from June 2014 to March 2015 to 
assist the clinical pharmacist with the PA process. Students developed their own 
protocol after their training to help improve the PA process, ensure the efficiency 
of PA requests for approval, management of appeal denials, and guidance on 
documentation of the PA progress within an electronic medical record. The 
students spent 240 hours for developing their protocol and completing PA 
requests. Overall, the students completed 88 requests with 87.7% approval rate. 
One of the positive sides of the student work is the saving time for the clinical 
pharmacist spent to provide clinical services and conduct academic activities. 
Beside their PA role, the students provided awareness to patients on their 
insurance coverage and followed treatment delivery. Moreover, the students 
trained a new team of peer students to ensure sustainability of the program 
(Martin, Telebak, Taylor, & Volozhina, 2016). 
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IV- Influencing Factors on Access to Hepatitis C Directly Acting 
Antivirals in Kentucky 
Hepatitis C Patients in Kentucky  
The Commonwealth of Kentucky is among of the top regions suffering 
from HCV across the US. Between 2009 and 2013, Kentucky reported the 
highest increase of new HCV cases nationwide with a two and half fold jump 
(National Center for HIV/AIDS, Viral Hepatitis, STD, 2015). In 2012, the state had 
the highest number of HCV cases among young non-urban persons in the US 
with 85 cases (Suryaprasad et al., 2014). The Appalachian southeast Kentucky 
possesses the highest prevalence of HCV infection among the state regions. 
This prevalence is predominantly among young adults who inject drugs. In 2013, 
a study suggested that more than half (54.6%) the PWIDs in Appalachia are 
infected with HCV (Havens et al., 2013). Statewide, the number of patients who 
are diagnosed and eligible for HCV treatment is not available.  
Kentucky Medicaid Program Prior Authorization Criteria 
In 2014, Kentucky state government established its own Medicaid 
expansion program “Kynect” following the directions set forth in the Affordable 
Care Act (ACA). Kynect led to a reduction in the state uninsurance rate by one 
half in one year (from 16% in 2013 to 8% in 2014) (Artiga, Tolbert, & Rudowitz, 
2016).  
The Medicaid program in Kentucky is considered one of the most 
restrictive programs in its PA criteria. Approval of DAAs for Medicaid 
beneficiaries in Kentucky requires: proof of advanced liver disease documented 
by a Metavir fibrosis score of F3 or F4; absence of decompensated cirrhosis 
corresponding to a Child–Pugh score class B or C; prescription by or in 
consultation with a specialist; i.e. hepatologist, gastroenterologist, or infectious 
diseases or LT clinician; and a proof of six months abstinence from substance 
abuse including drugs and alcohol (Barua et al., 2015). 
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Geographical Access to Hepatitis C Treatment in Kentucky 
Kentucky is Midwestern state covering an area of 39,728 square miles. In 
2015, 1,835,685 Kentucky residents lived in rural areas out of total of 4,425,092 
residents. The total number of hospitals in Kentucky is 103 of which 27 are 
Critical Access Hospitals. Kentucky has 109 Rural Health Clinics and 23 
Federally Qualified Health Centers (Rural Health Information Hub, 2015).  
In reference to the US Health Resources and Services Administration, 
underserved areas are those with a shortage in primary care providers, high 
infant mortality rates, high poverty rates, or a high elderly population. Following 
this definition, Kentucky is one of the medically underserved states with a total of 
350 health professional shortage areas including 151 primary care shortage 
areas.  Most of these shortage areas are located in the southeastern 
Appalachian region of the state. Within this shortage problem (figure 3), Kentucky 
patients infected with HCV, particularly those in southeast Kentucky, have limited 
choices for specialty care which are located either in central or northern Kentucky 
(Human Resources and Services Administration Data Warehouse, 2017). 
Figure 3. Geographical distribution of health professional shortage areas in 
Kentucky [Source: (Human Resources and Services Administration Data 
Warehouse, 2017)] 
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Characteristics of Kentucky Clinic Hepatitis C Patients 
In Kentucky Clinic, the Digestive Disease and Nutrition outpatient services 
had a total of 55,649 visits in the fiscal years 2010- 2015; 10,214 (18.35%) of 
these visits were done by HCV infected patients. Out of total 13,943 new patients 
visited the clinic in these five years there were 3,149 new patients infected with 
HCV (Abdelwadoud, Racho, & Rosenau, 2017).  
1- Sociodemographic Characteristics 
Over the period 2010-2015, the absolute number and proportion of new 
HCV patients among the total new patients increased significantly from 421 
(20.56%) in 2010-2011 to reach a peak of 1,071 new HCV patients (25.24%) in 
2014-2015. The mean age of new HCV patients was 42.36 (Standard Deviation 
[SD] +/- 12.69). By age group, 1,889 (59.99%) new HCV patients were born after 
1965 followed by 1,231 baby boomers (39.09%), and only 29 patients (0.92%) 
born before 1945. New male HCV patients were 1,683 (53.48%) while new 
female HCV patients were 1,465 (46.52%) (Abdelwadoud et al., 2017).  
2- Insurance Coverage 
Over the period 2010-2015, the new HCV patients who visited the 
Kentucky Clinic specialized Digestive Disease and Nutrition outpatient services 
were predominantly covered by Medicaid (1,582 patients corresponding to 
50.24%) followed by 1,130 patients (35.88%) on private or other types of 
insurance plans, and 437 (13.88%) were covered by Medicare (Abdelwadoud et 
al., 2017).   
3- Geographical Distribution 
The geographical distribution of new patients with HCV infection who 
visited the Kentucky Clinic Digestive Disease and Nutrition outpatient services in 
central Kentucky demonstrated that patients residing in the same county as the 
clinic; i.e. Fayette county, were 716 (22.74%), while non-Fayette County 
residents comprised 2,421 (76.88%), and 12 (0.38%) had no residency data 
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(figure 4). Non-Fayette residents were predominantly from rural Appalachian 
counties in southeastern Kentucky (Abdelwadoud et al., 2017).  
Figure 4. Geographical distribution of the Kentucky Clinic new patients 
with hepatitis C virus across Kentucky state counties 2010-2015 [Source: 
(Abdelwadoud et al., 2017)] 
 
This distribution of cases is different from some northern states. In 
Massachusetts, a study that analyzed HCV surveillance data from 2002 to 2013 
showed that reported HCV cases were highest in the most populous cities while 
smaller clusters were found around less population density cities and suburban 
areas (Goulart, n.d.). 
V-  Summary 
This literature review serves as a guide for understanding the complexity 
of access to the DAAs-based therapy for HCV. The all-oral standardized 
treatment is a breakthrough cure for a challenging virus to control since its 
discovery. HCV special criteria renders it a major challenge for the US health 
system. The virus methods of transmission are associated with risky behaviors 
that informed its prevention strategies; however, these strategies are limited to 
reducing the risk of exposure due to the unavailability of a prophylactic vaccine. 
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The prevalence and incidence of HCV in the US emphasizes that it is the top 
priority blood-borne infection and its burden will remain pressing for the coming 
years even though a curative treatment has been discovered. Several studies 
supported the above conclusion, the clinical complication of HCV are obviously 
consuming the healthcare system with high cost services.  
Various models for access to health services including general models, 
chronic diseases’ models, and HCV care models were employed in this review to 
guide its assessment of access to DAAs. The availability dimension of access 
revealed that the feasible diagnostic tools and the recently evolved highly 
effective and tolerable treatment open an opportunity for HCV elimination. 
Several studies showed the high effectiveness of DAAs in reducing morbidities 
and mortalities from HCV especially with early treatment. Collective evidence 
from different studies not only supports the curative role of the DAAs, but also 
their great potential to prevent transmission. On the other side, prescriber 
restrictions challenge mass provision of DAAs. Guidance from concerned 
organizations calls for utilizing and developing the expertise of different types of 
providers especially in underserved areas to fulfill the need for treatment. 
Moreover, almost all concerned organizations recommend expansion of 
screening for early treatment of HCV with DAAs. This expansion will drive a high 
demand represented by discovered and eligible patients for treatment. 
Consequently, this demand requires an equivalent responsive supply from a high 
acceptance and capacity health system. 
 Nevertheless, the treatment cascade and initiation rates at national level 
have shown insufficient response from the system especially in the last step from 
confirmation of diagnosis to treatment initiation. At organizational level, there is a 
large variability in treatment initiation rates suggesting that barriers are context 
specific and might be changing over time. Opposing these insufficient rates, 
ambitious projections anticipate a dramatic decrease in demand in the near 
future if the treatment would include all patients in need.  
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The concurrent characteristics of HCV patients in need for treatment 
shows that there are obvious changes compared the historical profile of HCV 
patients. Controversial results on patients’ characteristics among national and 
contextual studies invite an argument that these characteristics differ significantly 
across the US. The commonly accepted and representative studies point to 
Caucasian young non-urban Americans as the most affected by HCV, besides, 
the Caucasian patients have more likelihood to initiate treatment compared to 
other races. Substance abuse represents the key answer to the question what is 
the salient single character that predicts high HCV prevalence nowadays. While 
HCV and HIV have similar transmission methods, HCV prevalence is way higher 
among PWIDs. However, these disproportionately burdened high risk group is 
less favored in achieving HCV treatment initiation. In parallel, HIV/HCV co-
infection patients possess low rates of treatment initiation.  
The economic benefits of HCV treatment have been demonstrated by 
various studies. Cost-effectiveness in terms of QALYs favors strongly mass 
provision of DAAs. Several studies provided evidence on saving medical 
expenditure on future HCV complications in case of treating all patients in need. 
On the other hand, the national spending on DAAs increased tremendously over 
the past five years and peaked in the last two years. This spending is 
implemented under complex and different procedures in different health 
insurance organizations. While the sticker prices for DAAs are known, the key 
gap in this area is the unavailability of the final payed price by insurers to the 
pharmaceutical companies.  
Moreover, patients are disproportionately prone to cost sharing for DAAs 
according to their type of insurance coverage. The most recent studies on 
patients’ distribution among insurers reflect the change of epidemic towards 
young PWIDs and showed that the greatest portion of HCV patients is currently 
covered by Medicaid.  However, these patients are expected to fall under 
Medicare coverage in the near future with high probability of disease 
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complications coupled with higher costs then.  Another element to consider is the 
approval criteria set by different insurers for treatment initiation.  
Commercial insurance attempts to avoid HCV patients’ treatment or 
enforce cost sharing on them. Medicare is more accepting HCV treatment 
coverage through its attached prescription drug plans with less strict criteria 
compared to Medicaid. Most Medicaid programs select patients who are at 
advanced liver disease stages; not on drug abuse or abstained for a relatively 
long time; could reach out to a specialist for prescription; and engaged in ART 
therapy in case of HIV coinfection. These discriminative criteria aim at ensuring 
that the limited allocated financial resources would be targeting the best 
positioned patients to achieve cure with minimal probability of resistance, 
relapse, or recurrence of infection. Several organizations oppose this approach 
and refuted it from a legal perspective and offered cost reduction solutions. 
 As a result of these restrictive criteria for inclusion, PA approval rates in 
Medicaid are insufficiently low and disproportionately accept different types of 
patients compared to other types of insurances according to various studies in 
different states. Another important evidence against these restrictions comes 
from the evidence of cost-effectiveness of full-access treatment expansion which 
is supported by cost-reduction evidence from preventing morbidity costs on the 
whole healthcare system even though these patients would be probably covered 
by Medicare when they develop these morbidities.  
Most HCV specialized care is centralized in urban areas, this distribution 
opposes the distribution of patients within the increasing trend of HCV infection 
among rural residents. Evidence showed that geographical access to specialty 
HCV care can be singled out as the obstacle for treatment.  
Adding to all these obstacles, stigma and providers’ negative attitudes 
towards high risk patients hinder access to treatment. Several studies have 
shown the potential effectiveness of increasing awareness and reassurance of 
patients to overcome patients fears and misunderstandings.  
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Recommendations and best practices for HCV care delivery conclude that 
patients’ needs are the best guide. Meeting the patients where they 
conventionally access healthcare and offering testing and linkage to care at 
these convenient points, especially for difficult to reach groups, have been highly 
supported by several interventions’ results.  
Given the complex and often broken healthcare delivery system, patient 
navigators have been shown great results in ensuring continuity of care from 
testing to treatment initiation under several implementation models and 
depending on different personnel types.  
The ultimate option for care delivery is integration of care, a patient 
centered approach offering all needed services under one umbrella is the best 
option. Integrating HCV treatment into primary care, as well as integration with 
other vertical programs e.g. substance abuse and HIV ART, have been proven 
effective especially among high risk PWIDs in remote underserved areas. 
Moreover, integration within a holistic social service model including housing 
showed promising results.  
In support of the idea of integration, a primary care approach is a best 
match for HCV care. This approach requires task shifting from centralized 
specialty services to decentralized primary care proximal to the patients’ 
geographical and cultural needs. This approach is inspired by successful HIV 
models and with the effective and tolerable DAAs the results are expected to 
exceed those of HIV. However, task shifting is tied to capacity development of 
primary providers with technical support from specialty services. While some 
studies showed some hesitance among specialized and primary providers for 
assigning HCV treatment to the latter group, the success of Project ECHO and its 
expansion outweigh this hesitance if a well-established capacity development 
program was implemented. From another perspective, capacity development of 
HCV model of care should emphasize the administrative procedures. The two 
main support areas found useful are: maximizing the use of health information 
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system for linkage, continuity, and integration of care; and administrative support 
for the PA procedures with a specialized team.  
In Kentucky, the burden and patients’ characteristics are alarming. First 
and foremost, the state ranks high in HCV prevalence and incidence among the 
US with special hot spot of infection in Appalachian southeastern Kentucky 
attributed to the substance abuse epidemic. In contrast to this need, the 
Kentucky Medicaid program, which covers the majority of HCV patients, is very 
restrictive in applying criteria to the highest need group of PWIDs living in remote 
rural areas with limited geographical access to specialists. 
The Kentucky Clinic, this study setting, showed an escalating increase in 
utilization of specialized services by HCV patients from 2010 through 2015. The 
profile of these patients revealed that they are more commonly young males, 
Caucasians, and with Medicaid coverage. The geographic distribution of these 
patients demonstrated that more than three quarters were from outside the 
Clinic's direct catchment area and predominantly from rural southeastern areas 
of Kentucky.  
 Taken together, the review offered a comprehensive insight to the 
influencing factors on the access to DAAs from both the demand and supply 
sides. The problem is that there appears to be a vast gap between the promise 
from DAAs benefits and treatment initiation. Nevertheless, this review indicates 
that one size does not fit all when addressing access to DAAs. This gap pertains 
to fact that influencing factors vary among different contexts given that every 
context has special demand and supply profiles. A contextual understanding of 
the demand and supply in Kentucky requires practice oriented research to 
identify the particular characteristics of HCV care and gaps in care that need to 
be filled.  
VI-  Empirical and Theoretical Basis for This Study 
Given the high morbidity, mortality, and economic burdens of the HCV in 
Kentucky coupled with disparities in the potential for accessing the effective yet 
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costly DAA treatment, a study to investigate context specific barriers to treatment 
initiation is timely in order to address these barriers in Kentucky. Practice-
oriented research directed at the current HCV treatment obstacles in Kentucky is 
lacking, in addition, previous studies in this context are scarce and did not offer 
practical clues to the interrelated barriers to HCV treatment in Kentucky. To our 
knowledge, this is the first practice-based study to investigate the barriers to 
DAA-based treatment initiation in Kentucky.   
The interaction between HCV patients and the available model of care in 
Kentucky Clinic is specific to the Kentucky context. Accordingly, empirical 
exploratory research is highly valuable for addressing barriers to treatment 
initiation within this context. The conceptual model for this study, Figure 1, is 
adopted from several general and specific models to HCV care to capture all 
dimensions and possible factors influencing access to HCV treatment. The 
expected results from this study involve identifying the access barriers in the 
Kentucky clinic for HCV treatment initiation and proposing practice oriented 
feasible recommendations to overcome these barriers.  
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CHAPTER 3 
METHODOLOGY 
Chapter Overview 
The first part of this chapter sets the methodological approach; design; 
study setting; and target population for this study. Subsequently, how this study 
was implemented is answered by the methodological techniques used including: 
procedures, instrumentation and measurements, and analytical strategies. 
Ethical considerations were addressed and the summary sets for how this 
methodology is aligned with the study aims.  
I- Research Methodology 
Study Design 
Given that the supply and demand sides for access to health services do 
not exist in isolation, a mixed methods approach to comprehend the barriers for 
initiating HCV treatment among the Kentucky Clinic patients from both sides is 
required. 
The qualitative part used a set of qualitative techniques to explore the 
current model of care provided to HCV patients in the Kentucky Clinic. For the 
quantitative part, since the objective was to estimate the risk of the outcome i.e. 
initiation of treatment over time; the study utilized longitudinal cross-sectional 
data. Accordingly, the quantitative part followed a retrospective cohort design.  
The mixed results of these two parts were employed simultaneously to 
answer the research question of this study: what are the barriers for treatment 
initiation facing Kentucky Clinic HCV patients?  
Since the qualitative part pursues a real life description of the current 
model of care provided to the target population of the study, the null hypothesis 
in this case anticipates that the model of care perfectly enables access, fulfilling 
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the needs of HCV patients, and offering no obstacles for treatment initiation. The 
null hypothesis for the quantitative part assumes no significant difference in the 
characteristics of the patients who initiated treatment and those who did not.   
(H01) = there are no barriers associated with the current model of care for 
DAAs-based treatment initiation in the Kentucky Clinic.  
(H02) = there is no difference between the characteristics of the patients 
who initiate the DAAs-based treatment and those who do not initiate the 
treatment in the Kentucky Clinic.  
Study Setting 
The study was conducted in the specialized HCV outpatient clinic affiliated 
with the Digestive Diseases and Nutrition Division at the Kentucky Clinic. The 
Division outpatient services are recognized as the largest across Kentucky for 
their variety and number of providers. The Kentucky Clinic is located in Fayette 
County, Lexington City, Central Kentucky and is the major outpatient services 
facility affiliated with the University of Kentucky. The outpatient facility provides a 
wide variety of primary, secondary, and tertiary services in more than twenty 
specialized clinics supported by specialized pharmacies, laboratory, and 
radiological facilities. Outpatient services of the Kentucky Clinic are provided by 
more than four hundred healthcare providers (University of Kentucky Healthcare, 
2017) .  
Study Population  
For the qualitative part of the study, key informants were the 
administrative and clinical staff working closely with HCV patients through their 
journey from referral to treatment initiation. In the qualitative analysis the study 
cohort comprised all chronic HCV patients who had their first visit to the Kentucky 
Clinic's HCV clinic between July 1, 2014 and June 30, 2015.  
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Procedures  
Data collection took place from October through December 2016. The 
purpose of the qualitative part was to explore the model of care including the 
administrative and clinical procedures in the Kentucky Clinic applied to the 
patients seeking HCV treatment. This model and its applied procedures begin 
with the patient's referral to the Kentucky Clinic until the approval for treatment 
initiation is achieved. The quantitative part used data collected from the HCV 
clinic patients’ electronic medical records. The patients’ sociodemographic and 
clinical data are documented by the Kentucky Clinic administrative and clinical 
staff members during outpatient visits and maintained in a quality assured secure 
electronic medical records system. 
Instrumentation  
A- Qualitative Analysis: 
The qualitative analysis developed a real life administrative and clinical 
flowchart describing the current model of care provided for HCV patients in the 
Kentucky Clinic and identifying the obstacles to treatment initiation. In order to 
ensure data quality, qualitative measures to explore the model of care used 
different techniques for triangulation. Combining techniques aimed at increasing 
visibility about the treatment initiation process and ensuring comprehensiveness 
of the results. To achieve these purposes, the study investigator conducted: 
1- Field observations through attending the HCV clinic to observe and 
document the administrative and clinical procedures in practice;  
2- Semi structured in-depth interviews with healthcare personnel providing 
administrative and clinical services to hepatitis C patients in order to better 
understand these procedures and related barriers to treatment initiation. 
To ensure comprehensiveness, one provider from each provider 
categories was interviewed. Interviewees included: hepatology specialist, 
specialty clinical pharmacist, registered nurse, physician assistant, clinical 
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services technician, the clinic administrator, and the patient access 
manager. The topic guide for these interviews included three main 
inquiries: each interviewee’s roles and responsibilities relevant to the 
treatment initiation procedures, the barriers he/she founds hindering 
patients from treatment initiation, and his/her suggestions for overcoming 
these barriers.  
3- Administrative forms collection from the interviewees to better understand 
the process and ensure the quality of data.  
B- Quantitative Analysis: 
1- Outcome Variable 
Given the primary outcome of this analysis is treatment initiation, the 
outcome variable is defined as the initiation of all-oral treatment for chronic HCV 
either using a single DAA or a combination of DAAs, with or without RBV 
medication. To determine the predictive factors for DAAs treatment initiation, all 
patients were followed with an observation time calculated from the first visit of 
the patient to the Kentucky Clinic until treatment initiation or the last day of 
observation; i.e. November 30, 2016. For measurement, we constructed a 
treatment initiation binary variable (initiated treatment=1, did not initiate 
treatment=0).  
2- Explanatory variables 
Explanatory variables of interest in this analysis to assess the predictors 
for DAAs treatment initiation are: 
Sociodemographic Variables: 
1. Age: a discrete variable for patients’ completed years of age.  
2. Age group: we constructed the age group variable from the patients’ 
documented date of birth. This variable divides the study subjects into 
three age groups according to the year of birth:  before 1945, 1945-1965 
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(baby boomers with a historical high exposure to hepatitis C infection), 
and after 1965.  
3. Health insurance coverage: the patients' insurance coverage was 
constructed from the patients’ current primary payer into three classes: 
Medicare, Medicaid, and private or other types of insurance. 
4. Gender: binary variable of the patient’s genotypic gender defined as:  
male=1 and female=0. 
5. Race: the race variable has four categories: African-American, Asian, 
Caucasian, and Other races.   
6. County of residence: the medical records document the patient county of 
residence as a nominal variable. We constructed a simplified variable for 
the multivariate analysis with two classes: Fayette (the county where 
Kentucky Clinic is located-) and non-Fayette.  
7. Primary provider: although we consider the primary provider at the first 
visit less likely to influence the characteristics of the patient, we 
constructed a binary primary provider variable for statistical control 
purpose using a random provider assigned as 1 and all other providers in 
a reference class assigned as 0.  
8. Referring provider: the referring provider was created as a binary variable 
for the purpose of controlling the multivariate model.  
Clinical Variables 
9. Genotype: a dichotomous variable constructed into two levels; patients 
with a single HCV genotype and those with a combination of two or more 
genotypes (known to have some resistance for SVR that could alter the 
clinical or insurance decision for treatment initiation).   
10. Liver disease condition: a dichotomous variable constructed to classify the 
patients’ liver condition into two levels. Mild liver disease refers to patients 
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with F0-F2 score by METAVIR fibroscan; while advanced liver disease 
refers to patients with F3 score or above, or evidence of cirrhosis by 
another diagnostic tool.   
11. Follow-up: binary variable to differentiate patients who had at least one 
follow up visit after their initial visit to the clinic (assigned as 1) and those 
without any follow-up history (assigned as 0).  
Behavioral Variable: 
12. Substance abuse: a binary variable classifying patients into those with 
history of drug abuse (assigned as 1) and those without (assigned as 0).   
Analysis Strategy 
Qualitative Analysis: 
Data collected from the field observation notes, in-depth interviews, and 
administrative forms' review were gathered to describe the current model of care 
covering the administrative and clinical procedures for treatment initiation.  
Quantitative Analysis: 
Using the Statistical Analysis Software (SAS) 9.4 package (SAS Institute 
Inc., Cary, North Carolina), quantitative analysis was conducted in two stages: 
1- Descriptive Analysis: 
A descriptive analysis was performed to tabulate the frequencies and 
percentages of patients’ explanatory variables comparing those who initiated 
treatment to those who did not. In this analysis we used frequencies and 
percentages for the categorical explanatory variables. For the only discrete 
variable, age, we used means, standard deviations, and the student’s t-test to 
assess significance.  
2- Time to Treatment Analysis: 
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Cumulative incidence of treatment initiation was calculated over the study 
period and Kaplan–Meier time to treatment analysis was used to construct time 
to treatment curves estimating the proportion of patients who initiated treatment 
at different time points comparing each explanatory variable levels.  
Cox Proportional Hazards Regression analysis was conducted to identify 
predictive independent variables for treatment initiation over time using the 
relative risk estimate hazard ratio (HR) and 95% confidence intervals. Dummy 
variables for every explanatory variable were constructed to include them in the 
model with a reference first class for comparison. 
The Cox regression analysis aimed at fitting all explanatory covariates 
including: age group, gender, race, health insurance coverage, county of 
residence, primary provider, referring provider, genotype, liver disease condition, 
follow-up, and substance abuse. We employed interaction terms assuming that 
the age group, insurance coverage, and liver disease condition are interrelated 
based on the fact that the majority of Medicare patients are older and probably 
experienced HCV for a long period of time, they are probably more susceptible 
for advanced liver disease reference to the natural history of HCV. Moreover, the 
PA approval for treatment initiation mandates advanced liver disease for 
Medicaid patients. Accordingly, the final model fitted all covariates of the first 
model while interaction terms were applied for the assumed interrelated 
covariates.  
All tests were 2-tailed with a significance level of 0.05; i.e. a p-value less 
than 0.05 (two-tailed) was considered to be statistically significant. 
II- Ethical Statement 
The work described was approved by the Institutional Review Board of the 
University of Kentucky Office of Research Integrity. 
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III- Summary 
Using mixed methods in this study aimed at improving the depth and the 
breadth of the analysis for comprehensive understanding of HCV treatment 
initiation barriers. The qualitative part of the study should reveal insights into how 
the model of care may hinder the outcome of the study. Simultaneously, the 
quantitative part compares the characteristics of patients who achieved and who 
did not achieve the outcome in addition to assessing the predictors among these 
characteristics for outcome achievement. Collective results from both analyses 
would help propose a comprehensive model of care enabling HCV patients 
access treatment based on the needs identified from the current model of care 
and patients’ characteristics. 
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CHAPTER 4 
RESULTS 
Chapter Overview 
This chapter presents the study results in two sections: qualitative and 
quantitative analyses. A joint interpretation of these results then follows in order 
to simultaneously understand the barriers that hinder the Kentucky Clinic HCV 
patients from initiating DAA-based treatment. 
I- Qualitative Results 
Results of the data collected from the field observation notes, in-depth 
interviews, and administrative forms' review reveal that the current model of care 
provided for HCV patients is linear (figure 5). The patient’s journey begins when 
the referring provider, in most cases the patient’s primary provider, issues a 
referral for HCV assessment by a HCV specialist clinician. The first 
administrative procedure occurs at the University of Kentucky Patient Access 
Center located nearly five miles from the Kentucky Clinic.  
The Patient Access Center is responsible for receiving the referral calls 
from the referring facility and scheduling patients for a specialist appointment at 
the hepatitis C clinic either at the Kentucky Clinic or at the University of Kentucky 
Good Samaritan Hospital. While the Good Samaritan Hospital offers specialized 
HCV services, patients are referred after the first appointment for follow-up at the 
Kentucky Clinic due to the availability of the HCV specialist pharmacy. The 
obvious barrier at this initial step is the clinical information gap. Accordingly, 
incomplete clinical data leads to potential inaccurate prioritization of patients in 
scheduling.  
The first appointment for HCV assessment is given to the patient based on 
the first available appointment either with a mid-level HCV specialist or a higher 
level attending physician at either clinic. The total number of specialists at the 
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time of this study was twelve, only one of them accepts HCV patients in her 
outpatient services, while the others accept patients in their specialized half day 
HCV clinic. Due to the limited availability of appointments with either level of 
specialists, the average waiting time for the first appointment at the Kentucky 
Clinic ranges from three to six months. Occasionally, a special note from the 
referring provider recommending an appointment with an attending physician 
results in a longer waiting time due to the limited number of appointments offered 
by the attending physicians. On the other hand, a priority note for an urgent 
clinical condition allows the Patient Access Center to find an earlier appointment.  
Ensuring patient compliance with the scheduled appointment is 
jeopardized by several factors including: no response to the scheduling call from 
the Patient Access Center, change of phone number, lack of transportation on 
the day of the appointment, and more predominantly the patient’s perception that 
the appointment and the HCV treatment in general are of low importance. On the 
other hand, appointment cancellation by the specialist is a potential hazard. In 
this case, rescheduling takes up to six weeks after the initially scheduled 
appointment.  
In almost all cases the patient is not prepared by his/her referring provider 
for the administrative and clinical procedures he/she will follow at the Kentucky 
Clinic for treatment approval. During the first appointment, the specialist 
assesses the patient referral papers and previous laboratory and radiological 
investigations if available. Clinical assessment includes questions about: history 
of HCV transmission methods with special emphasis on substance abuse 
practices, onset of HCV infection discovery, comorbidities and general clinical 
assessment, results of previous laboratory and radiological investigations, and 
whether there are missing investigations in the patient’s records. A common 
challenge at this point is the non-availability of laboratory or radiological results 
especially those done outside the Kentucky Clinic. Moreover, results requested 
by the clinic from other facilities are received by fax causing a delay. 
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Due to lack of awareness among the majority of patients about HCV, the 
specialist offers a standard awareness message about HCV methods of 
transmission, measures for prevention, and how to protect the patient’s close 
contacts. Finally, the specialist provides a general message on the current 
clinical status; the next plan including the required clinical, laboratory, and 
radiological assessments; possible prognosis; and an emphasis on the 
importance of compliance.  
After the appointment, the specialist clinician orders laboratory and 
radiological investigations with two objectives: full clinical assessment and 
compliance with the PA requirements. Given the second objective, this order is 
completed in consultation with the HCV specialist pharmacist in the clinic. In few 
cases, patients with urgent clinical conditions; e.g., urgent follow-up 
appointments are requested for individuals with liver decompensation.   
After the first appointment, follow-ups are scheduled by the patient. The 
second appointment, which may occur up to two months after the first 
appointment, aims at finalizing the administrative and clinical procedures 
required to comply with the treatment PA requirements. In most cases, the 
specialist clinician assesses the ordered laboratory and radiological 
investigations and conducts or orders a fibroscan procedure if not previously 
done. A potential challenge is identifying advanced liver disease in Medicaid 
patients since the fibroscan assessment for the F3 level has no clear cuts and 
inconsistency occurs among the clinicians conducting it. Besides, other evidence; 
e.g., cirrhosis in the liver biopsy, can waive this fibrosis level. Most clinicians 
employ supplementary investigations plus their clinical assessment to make the 
final decision on the stage of liver disease. 
In parallel, the specialist pharmacist reviews the patient’s full record 
including illicit drug laboratory results and communicates with clinical and 
administrative personnel as necessary to ensure compliance with the PA 
requirements of the patient’s specific insurer. These requirements vary among 
different insurers and the insurer's case-to-case flexibility is variable as well. The 
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chosen DAA protocol is assigned to the patient according to his/her clinical 
profile and usually this choice does not impact the PA decision.  
When the patient’s PA file is completed, the specialist pharmacist 
administers the PA procedures with the insurer on behalf of the patient 
(appendices 1 and 2). Time to PA decision varies according to the type of 
insurer. In case of PA disapproval, the specialist pharmacist conducts an appeal 
(appendix 3) supported by laboratory and radiological investigations in 
consultation with the specialist clinician. The appeal process takes from one to 
two months on average.  
Once the PA is approved, the specialist pharmacist works jointly with the 
clinical services technician; i.e. case manager, on implementing the DAAs 
treatment protocol (appendices 4 and 5). The first step is informing the patient 
about the approval, followed by patient education sessions supported by 
handouts about: the natural history of HCV and its prognosis, general 
precautions for liver protection, goals of treatment and its effectiveness, the 
potential side effects of the DAAs, and the treatment plan with special emphasis 
on the importance of compliance to achieve cure (appendix 6).  
The treatment administrative plan is standardized for all patients and 
follows the DAAs twelve-week protocol (appendix 7). After the initial DAAs visit, 
there is a two-week laboratory assessment for which the patient has the option to 
take the laboratory tests at a proximal facility for geographical convenience. The 
specialist pharmacist or the case manager calls the patient on the day of the 
laboratory assessment to ensure compliance and offers support or modification 
the plan if the patient is not able to take the tests. In the fourth week, the patient 
visits the clinic for clinical follow-up and to ensure compliance. In the eighth 
week, the patient undergoes a laboratory assessment similar to the second week 
with another call from the specialist pharmacist or the case manager. At the end 
of treatment, the twelfth week, the patient visits the clinic for the final treatment 
and compliance follow-up.   
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These five follow-up visits are documented in a special pre-organized 
patient follow-up and outcomes Microsoft Office Excel® spreadsheet (Appendix 
8) including all administrative and clinical follow-up data. In parallel, the specialist 
pharmacist conducts a follow-up clinical assessment survey with the patient 
focusing mainly on the patient reported clinical outcomes during each follow-up 
visit or phone call. In case of the patient’s failure to comply, there are three 
phone call reminders followed by a certified letter to the patient’s physical mailing 
address. While these well-established personalized follow-up procedures can 
ensure compliance, the integration of care with other services; e.g. primary care 
services and substance abuse programs is a major concern.  
The post-treatment assessment of SVR is based on quantitative HCV 
RNA test conducted on the fourth, twelfth, and twenty-fourth weeks after end of 
treatment. The last SVR test is accompanied by an in-clinic visit for clinical 
assessment. 
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Figure 5. The current model of care and its administrative and clinical procedures applied to Hepatitis C patients 
seeking the DDA-based treatment at the Kentucky Clinic 
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II- Quantitative Results 
1- Descriptive Analysis: 
A total of 880 HCV patients visited the HCV clinic at the Kentucky Clinic 
between July 1, 2014 and June 30, 2015. Descriptive analysis (table 1) revealed 
that only 195 (22.16%) patients initiated the DAAs treatment during the 
observation period; i.e. until November 30, 2016, while 685 (77.84%) patients did 
not initiate treatment. The mean age of all patients was 43.04 years (Standard 
Deviation [SD] +/- 12.36). The mean age of the patients who initiated treatment 
was significantly higher (51.55 years +/-10.4) compared to the mean age of the 
patients who did not initiate treatment (40.62 years +/-11.79), p-value < 0.0001.  
When stratified according to year of birth categories, the age group of the 
baby boomers who initiated treatment comprised the highest proportion (66.67%) 
followed by those born after 1965 (32.31%) followed by the oldest group; i.e. 
those born before 1945 (1.03%). This distribution contrasted the fact that those 
born after 1965 represented the highest proportion (63.86%) of the entire study 
cohort.  
The insurance type distribution showed that the 645 Medicaid patients, 
representing 73.30% of the whole study cohort, comprised less than half 
(47.18%) of the patients who initiated treatment followed by Medicare patients 
(28.72%) then private and other insurance patients (24.10%). The initiation rate 
among Medicaid patients was the lowest (14.26%) compared to Medicare 
(49.56%), and private and other types of insurance patients (38.52%).  
Male patients comprised nearly two thirds (63.08%) of the patients who 
initiated treatment while females comprised nearly one third (36.92%). Racial 
group distribution of the study participants reflected the predominant Caucasian 
population in Kentucky. However, only 20.66% of the Caucasian participants 
initiated treatment compared to 44.45% of the African American participants. This 
distribution should not be mixed with the distribution of patients who initiated 
treatment showing that Caucasians were the most prevalent (86.67%) followed 
85 
 
by African Americans (12.28%) while only one patient (0.15%) was from the 
Asian and the unreported race group.  
About three quarters of the patients who initiated treatment resided 
outside the Fayette county (73.85%) while nearly one quarter (26.15%) resided in 
the Fayette county. 
The patients who initiated treatment with a single genotype represented 
97.74% while those with combined genotype represented 2.06% (42 patients 
from the whole cohort did not have a reported genotype in their records, only one 
of them was among the patients who initiated treatment).  
Although the patients with mild liver disease comprised 63.75% of the 
whole cohort, they represented only 29.74% of the patients who initiated 
treatment compared to the patients who initiated treatment and were at an 
advanced liver disease stage (70.26%). Only two patients (1.03%) did not have 
any follow-up visits and could not initiate treatment. The majority of the study 
cohort had a history of substance abuse (72.95%) and represented the highest 
proportion of the patients who initiated treatment (62.05%). However, the 
proportion for the patients without history of substance abuse who initiated 
treatment is lower (18.85% of the substance abuse participants) compared to 
those who had no history of substance abuse (31.1% of the participants with no 
history of substance abuse).  
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Table 1: Frequency distribution and percentages of the characteristics of the 
Kentucky Clinic hepatitis C patients who initiated vs. who did not initiate 
hepatitis directly acting antiviral therapy (July 2014 - November 2016) 
 
Measure 
 
Levels of 
Measurement 
Initiated 
Treatment 
 Frequency 
(Percentage per 
total initiated, 
Percentage per 
measure level)  
Did not Initiate 
Treatment 
Frequency 
(Percentage per 
total did not  
initiate, 
Percentage per 
measure level) 
Total  
Frequency 
(Percentage per 
measure group) 
Sociodemographic Variables 
Mean Age  
(+/- Standard Deviation) 
51.55  
(+/-10.4)* 
40.62  
(+/-11.79) 
43.04  
(+/-12.36) 
Age Group Born before 1945 2  
(1.03%, 50%) 
2  
(0.29%, 50%) 
4  
(0.45%) 
Born 1945-1965 130  
(66.67%, 41.40%) 
184  
(26.86%, 58.60%) 
314  
(35.68%) 
Born after 1965 63  
(32.31%, 11.21%) 
499  
(72.85%, 88.79%) 
562  
(63.86%) 
Insurance 
Coverage 
Medicare 56  
(28.72%, 49.56%) 
57  
(8.32%, 50.44%) 
113  
(12.84%) 
Medicaid 92  
(47.18%, 14.26%) 
553  
(80.73%, 85.73%) 
645  
(73.30%) 
Private and other 
types of insurance 
47  
(24.10%, 38.52%) 
75  
(10.95%, 61.48%) 
122  
(13.86%) 
Gender Females 72  
(36.92%, 17.43%) 
341  
(49.78%, 82.57%) 
413  
(46.93%) 
Males 123  
(63.08%, 26.34%) 
344  
(50.22%, 73.66%) 
467  
(53.07%) 
Race African American 25  
(12.82%, 45.45%) 
30  
(4.38%, 54.55%) 
55  
(6.25%) 
Caucasian 169  
(86.67%, 20.66%) 
649  
(94.74%, 79.34%) 
818  
(92.95%) 
Asian and 
unreported 
1  
(0.51%, 14.29%) 
6  
(0.88%, 85.71%) 
7  
(0.80%) 
County of 
Residence 
Non-Fayette 144  
(73.85%, 21.18%) 
536  
(78.25%, 78.82%) 
680  
(77.27%) 
Fayette 51  
(26.15%, 25.50%) 
149  
(21.75%, 74.50%) 
200  
(22.73%) 
Primary 
Provider 
Chosen 42  
(21.54%, 20.59%) 
162  
(23.65%, 79.41%) 
204  
(23.18%) 
Others 153  
(78.46%, 22.63%) 
523  
(76.35%, 77.37%) 
676  
(76.82%) 
Referring 
Provider 
Unknown 8  
(4.10%, 14.55%) 
47  
(6.86%, 85.45%) 
55  
(6.25%) 
Others 187  
(95.90%, 22.67%) 
638  
(93.14%, 77.33%) 
825  
(93.75%) 
Clinical Variables  
Genotype** Single 190  
(97.94%, 23.11%) 
632  
(98.14 %, 76.89%) 
822  
(98.09%) 
Combined 4  
(2.06%, 25%) 
12  
(1.86%, 75%) 
16  
(1.91%) 
Liver Condition Mild liver disease 58  
(29.74%, 10.34%) 
503  
(73.43%, 89.66%) 
561  
(63.75%) 
Advanced liver 
disease 
137  
(70.26%, 42.95%) 
182  
(26.57%, 57.05%) 
319  
(36.25%) 
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Table 1: Frequency distribution and percentages of the characteristics of the 
Kentucky Clinic hepatitis C patients who initiated vs. who did not initiate 
hepatitis directly acting antiviral therapy (July 2014 - November 2016) 
Continued  
 
Measure 
 
Levels of 
Measurement 
Initiated 
Treatment 
 Frequency 
(Percentage per 
total initiated, 
Percentage per 
measure level)  
Did not Initiate 
Treatment 
Frequency 
(Percentage per 
total did not  
initiate, 
Percentage per 
measure level) 
Total  
Frequency 
(Percentage per 
measure group) 
Follow Up No follow-up 2  
(1.03%, 0.62%) 
322  
(47.01%, 99.38%) 
324  
(36.82%) 
Follow-up at least 
once 
193  
(98.97%, 34.71%) 
363  
(52.99%, 65.29%) 
556  
(63.18%) 
Behavioral Variable  
Substance 
Abuse 
No history of 
substance abuse 
74  
(37.95%, 31.09%) 
164  
(23.94%, 68.91%) 
238  
(27.05%) 
History of substance 
abuse 
121  
(62.05%, 18.85%) 
521  
(76.06%, 81.15%) 
642  
(72.95%) 
Total 195 (22.16%) 685 (77.84%) 880 (100%) 
*The difference between the mean age of patients who initiated and who did not initiate treatment 
is statistically significant (p-value=<0.0001) 
**The number of patients whose genotype was missing = 42. 
2- Time to Treatment Analysis  
The average number of days to initiate treatment starting from the 
patient’s first visit to the Kentucky Clinic was 263.57 days with a minimum of 30 
days and a maximum 793 days to initiate treatment. The cumulative incidence 
showed that the probability for DAAs treatment initiation at 203 days or less was 
50%; i.e. the median number of days to treatment, then this probability 
accumulated at slower rate (figure 6).  
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Figure 6. Cumulative distribution function of days to directly acting 
antiviral treatment initiation for the Kentucky Clinic hepatitis C patients 
(July 2014 - November 2016) 
 
The Kaplan–Meier time to treatment curves estimated the proportion of 
patients who initiated treatment at different time points (figures 7-16). Significant 
results from these curves demonstrated that gender, race, follow-up, substance 
abuse, and age group affected the likelihood of treatment initiation over time. At 
different time points, earlier treatment initiation times were found among: males 
compared to females (log rank p-value = 0.0016); African Americans followed by 
Caucasians then Asians and patients with unreported race (log rank p-value = < 
0.0001); patients who had at least one follow-up visit compared to those who 
declined follow-up (log rank p-value = < 0.0001); patients with no history of 
substance abuse compared to those who had history of substance abuse (log 
rank p-value = < 0.0001). 
By age group, the patients who were born before 1945 and baby boomers 
initiated treatment earlier than those born after 1965 (log rank p-value = < 
0.0001). By insurance type, the patients who were on Medicare initiated 
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treatment the earliest followed by private or other types of insurance patients 
then those on Medicaid (log rank p-value = < 0.0001). Liver disease condition 
curves demonstrated that patients with advanced liver conditions initiated 
treatment earlier than patients with mild liver disease (log rank p-value = < 
0.0001).  
On stratifying the patients’ insurance type by their liver disease condition, 
the Kaplan–Meier time to treatment curves showed that patients’ covered by 
private or other insurance types with advanced liver disease were the earliest to 
initiate treatment, while Medicaid patients with mild liver disease were the latest 
to initiate treatment. 
Figure 7. Kaplan-Meier estimates for DAAs treatment initiation by gender 
with 95% Hall-Wellner confidence bands 
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Figure 8. Kaplan-Meier estimates for DAAs treatment initiation by race with 
95% Hall-Wellner confidence bands 
 
Figure 9. Kaplan-Meier estimates for DAAs treatment initiation by county of 
residence with 95% Hall-Wellner confidence bands 
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Figure 10. Kaplan-Meier estimates for DAAs treatment initiation by 
genotype with 95% Hall-Wellner confidence bands 
 
Figure 11. Kaplan-Meier estimates for DAAs treatment initiation by follow-
up with 95% Hall-Wellner confidence bands 
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Figure 12. Kaplan-Meier estimates for DAAs treatment initiation by history 
of substance abuse with 95% Hall-Wellner confidence bands
 
Figure 13. Kaplan-Meier estimates for DAAs treatment initiation by year of 
birth with 95% Hall-Wellner confidence bands 
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Figure 14. Kaplan-Meier estimates for DAAs treatment initiation by 
insurance type with 95% Hall-Wellner confidence bands 
 
Figure 15. Kaplan-Meier estimates for DAAs treatment initiation by liver 
disease condition with 95% Hall-Wellner confidence bands 
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Figure 16. Kaplan-Meier estimates for DAAs treatment initiation by 
insurance type and liver disease condition with 95% Hall-Wellner 
confidence bands 
 
In the Cox proportional hazards regression analysis, we included the 
hypothesized interaction terms of age, insurance type, and liver disease 
condition plus all other covariates. To fit the best model, we followed a backward 
elimination strategy to include the significant interactions only, we also excluded 
the age group of patients born before 1945 where only two patients initiated 
treatment. The final model (table 2a and 2b) fit statistics showed that Akaike’s 
Information Criterion (AIC) for intercept and covariates is lower (AIC = 2193.189) 
than the initial model (AIC = 2221.310).  
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Tables 2a and 2b. Estimates from the final Cox proportional hazards 
regression model for the characteristics of the Kentucky Clinic hepatitis C 
patients  
2a 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
P-
Value 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits Reference 
History of 
Substance 
Abuse 
1 -0.00807 0.15545 0.0027 0.9586 0.992 0.731 1.345 No history 
of 
substance 
abuse 
Male 1 0.03615 0.15631 0.0535 0.8171 1.037 0.763 1.408 Female 
Follow-up 
at least 
one visit 
1 3.97326 0.71312 31.0435 <.0001 53.157 13.139 215.066 No follow-
up 
Fayette 
County 
Residency 
1 0.09086 0.19298 0.2217 0.6377 1.095 0.750 1.599 Non-
Fayette 
county 
residency 
African 
American 
1 0.26653 0.25386 1.1023 0.2938 1.305 0.794 2.147 Caucasian 
Asian or 
Unreported 
Race 
1 0.07336 1.01640 0.0052 0.9425 1.076 0.147 7.889 Caucasian 
Combined 
Genotype 
1 0.00175 0.52416 0.0000 0.9973 1.002 0.359 2.799 Single 
genotype 
Chosen 
Primary 
Provider 
1 -0.07425 0.18038 0.1695 0.6806 0.928 0.652 1.322 All other 
primary 
providers 
Unknown 
Referring 
Provider 
1 -0.19755 0.37543 0.2769 0.5987 0.821 0.393 1.713 All other 
referring 
providers 
*Significant values at alpha level of 0.05 and Confidence Limits not including the null value i.e. 1, 
are in bold. 
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2b 
Hazard Ratios for Insurance Types vs. Age Groups at Advanced Liver Disease Stage 
Description 
Point 
Estimate 
95% Wald 
Confidence Limits 
Medicare vs. Medicaid baby boomers (born 1945-1965) 1.703 1.079 2.688 
Medicare vs. Private and Other Insurance baby 
boomers (born 1945-1965) 
0.727 0.432 1.223 
Medicaid vs. Private and Other Insurance baby 
boomers (born 1945-1965) 
0.427 0.267 0.682 
Medicare vs. Medicaid patients born after 1965 5.055 2.356 10.846 
Medicare vs. Private and Other Insurance patients 
born after 1965 
1.384 0.588 3.258 
Medicaid vs. Private and Other Insurance patients 
born after 1965 
0.274 0.131 0.573 
Hazard Ratios for Insurance Types vs. Age Groups at Mild Liver Disease Stage 
Description 
Point 
Estimate 
95% Wald 
Confidence Limits 
Medicare vs. Medicaid baby boomers (born 1945-1965) 4.501 2.176 9.307 
Medicare vs. Private and Other Insurance baby 
boomers (born 1945-1965) 
1.709 0.740 3.944 
Medicaid vs. Private and Other Insurance baby 
boomers (born 1945-1965) 
0.380 0.164 0.881 
Medicare vs. Medicaid patients born after 1965 13.359 6.203 28.770 
Medicare vs. Private and Other Insurance patients 
born after 1965 
3.252 1.349 7.843 
Medicaid vs. Private and Other Insurance patients 
born after 1965 
0.243 0.117 0.508 
*Significant values at alpha level of 0.05 and Confidence Limits not including the null value i.e. 1, 
are in bold. 
Adjusting for other covariates, significant Hazard ratio results from the final 
model (tables 2a and 2b) demonstrated that: 
The likelihood of treatment initiation over time at the advanced liver 
disease stage for the baby boomers (born between 1945 and 1965) on Medicare 
is 1.7 times that of their age group counterparts on Medicaid (CI 95%, 1.079 - 
2.688). Within the same age group and at the same liver disease stage, Medicaid 
patients possess 0.43 times the likelihood of private and other types of insurance 
patients (CI 95%, 0.267 - 0.682). For the younger patients born after 1965 and at 
advanced liver disease stage, the Medicare patients' likelihood for treatment 
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initiation is 5.06 times those on Medicaid coverage (CI 95% 2.356 - 10.846) who 
have only 0.27 times the likelihood of private and other insurance patients to 
initiate treatment (CI 95% 0.131 - 0.573) 
On the other hand, the mild liver disease patients’ treatment initiation 
likelihood over time results revealed that baby boomers on Medicare are 4.5 
times as likely as Medicaid baby boomers to initiate treatment (CI 95%, 1.079 - 
2.688) while Medicaid patients have only 0.38 times the likelihood of private and 
other types of insurance patients (CI 95%, 0.164 - 0.881). The Medicare patients 
born after 1965 and at mild liver disease stage have 13.36 times the likelihood of 
those on Medicaid coverage (CI 95% 6.203 - 28.770) and 3.25 those on private 
and other types of insurance patients (CI 95% 1.349 - 7.843). These Medicaid 
patients, at mild liver disease stage and born after 1965, have only 0.24 times the 
likelihood of private and other insurance patients to initiate treatment (CI 95% 
0.117 - 0.508) 
The results showed no significant difference in the treatment initiation 
likelihood over time between Medicare versus private and other types of 
insurance at any stage of liver disease except the aforementioned likelihood of 
mild liver disease patients born after 1965. 
III- Summary 
Multiple interrelated difficulties in accessing the DAAs treatment were 
found of relevance to the current model of care and patients’ characteristics. The 
treatment initiation journey is long and hindered by complicated stepwise 
administrative and clinical procedures. Lack of proper communication between 
the referring facility, the scheduling center, and the HCV clinic is obvious. 
Moreover, lack of awareness among the patients and their referring provider 
concerning the treatment initiation procedures add to the difficulty in 
communication. The administrative and clinical procedures are centered around 
the PA requirements. Medicaid applied restrictive criteria favoring advanced liver 
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disease patients which requires a clinical proof difficult to achieve in border line 
cases between the mild and advanced liver disease stages.  
Under the current restrictive PA requirements, the overall rate and 
characteristics of the patients who initiate treatment are not satisfactory. 
Disproportionate access to treatment is found among Medicaid patients, younger 
patients born after 1965, and those with mild liver disease. The time to treatment 
analysis is consistent with these findings. 
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CHAPTER 5 
IMPLICATIONS FOR PUBLIC HEALTH 
I- Discussion 
Several barriers to HCV treatment initiation have been identified in the 
current model of care. Referral and scheduling are strictly administrative in 
nature lacking adequate clinical information, reflecting the patient’s needs, 
leading to a potential inadequate preparation before the first visit to the Kentucky 
Clinic HCV services. 
Moreover, there is an obvious inadequate communication between the 
Patient Access Center and the Kentucky Clinic during the scheduling process 
compounded by the geographical distance between the two facilities. In addition, 
the waiting time for the first visit at the Kentucky Clinic is long. From the patient 
side, several factors favor non-compliance with the scheduled appointment plus 
the possibility of cancellation by the HCV specialist.  
On the patient first visit at the HCV clinic, lack of patient awareness about 
the disease and the DAAs treatment clinical and administrative procedures are 
major obstacles. This barrier was underscored elsewhere as one of the major 
barriers to treatment (Grebely, Oser, Taylor, & Dore, 2013). Moreover, the 
referring provider in most cases is not aware of these procedures at the Kentucky 
Clinic adding to the inadequate preparation problem. The San Francisco safety 
net healthcare system experience offers an opportunity to overcome this obstacle 
through mandatory educational training for the patients prior to the clinical 
assessment for the DAAs treatment initiation (Lubega, Agbim, Surjadi, Mahoney, 
& Khalili, 2013).  
Deficient linkage to care and patient education have been addressed 
collectively in several contexts through a patient navigation system (Ford, 
Johnson, Desai, Rude, & Laraque, 2016) which is lacking in the Kentucky Clinic 
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although the specialist pharmacist and the case manager offer navigation roles in 
a limited part of the patient journey particularly inside the clinic.  
In fact, several questions for a successful and context specific patient 
navigation system require answers. First, when and how to start this system, 
should it be at the point of referral or earlier at the point of discovery which can 
be driven by an active screening program? A comprehensive navigation system 
using mobile clinics for screening, linkage, and continuation of care throughout 
the journey to treatment initiation showed successful results in answering this 
question (Trooskin et al., 2015). Mobile clinics were proven effective in 
discovering patients in high prevalence remote areas and linking them to 
standardized DAAs treatment (Morano et al., 2014). 
Second, who should be assigned this role? Social workers and community 
health workers has been assigned patient navigation roles where the latter were 
chosen from local communities to ensure cultural acceptance (Ford et al., 2016; 
Ramirez et al., 2016). In some models of patient navigation, this role is assigned 
to a counseling psychologist to accommodate patients practicing risky behaviors; 
e.g., IDU, or those incarcerated (Allison et al., 2016; Seña et al., 2016).  
Third, what should these navigators offer? Comprehensive services based 
on the patients’ needs and including a fundamental educational component is 
appropriate, but its implementation requires personalization of these services. A 
patient needs assessment has been utilized as the first tool in the navigation 
process and showed successful results in elevating treatment initiation rates 
(Glick, Armstrong, Tobin, & Allgood, 2016).  In general terms, the more 
comprehensive the navigation model is, the better the results  (Linas et al., 
2014).   
Adding to the improper education and preparation obstacles, laboratory 
and radiological investigations performed outside the Kentucky Clinic requires 
time for retrieval in order to reach the patient’s record. In parallel, clinical 
procedures to prepare the patient are complex especially for proving a condition 
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of advanced liver disease in order to comply with Medicaid PA requirements. The 
second visit of the patient, which is intended to finalize the PA requirements, is 
usually scheduled far from the first visit, one important cause of this delay is the 
time needed for completion of laboratory and radiological investigations. Insurers 
have variable approval requirements; the Medicaid program is the most 
demanding and restrictive. However, even within Medicaid, insurers are variable 
in their flexibility and acceptance of advanced liver disease evidence. In case the 
PA request is disapproved, another lengthy appeal process adds to the patient’s 
delay in initiating treatment.  
The health information system within the Kentucky Clinic is well 
established and efficient; however, data linkage to other healthcare facilities 
including the referral facilities could offer greater support to the linkage and 
continuity of care needs and overcome the delay in arrival or inability to retrieve 
the laboratory and radiological studies done outside the Clinic. Data linkage 
offered successful results in this area connecting substance abuse programs with 
specialized HCV services (Hochstatter et al., 2017). Speeding up the PA process 
and the possible appeal process at the Kentucky Clinic should benchmark with 
the pharmacy students-based model that offered excellent support to the 
specialist pharmacists and improved the PA process overall (Martin, Telebak, 
Taylor, & Volozhina, 2016).   
In addition to the within model of care obstacles, integration with other 
services is not provided. Integration of services is a cornerstone for a successful 
and comprehensive model of care and is based on the patient centered health 
services principle. The ideal integration approach is holistic in nature including 
HCV supportive services; e.g., the patient navigation system and educational 
programs, in addition to other services outside the HCV services based on the 
patient’s needs (Allison et al., 2016; US Department of Health and Human 
Services, 2011). Best practices evidence expanded the integrated services to 
involve other social services as well (Maier, Ross, Chartier, Belperio, & Backus, 
2016). To implement this approach, a multidisciplinary team of providers was 
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employed in several contexts including HCV, HIV, and substance abuse 
providers (Bruggmann & Litwin, 2013; Butner et al., 2017). The best setting to 
initiate and coordinate this integrated approach is at the place where the patient 
accesses his/her health services and the most accessible facility for him/her; 
e.g.,  a primary care or substance abuse management facility (Akyar et al., 2016; 
Bruggmann & Litwin, 2013; Jayasekera et al., 2017; Zeremski et al., 2013). 
Similar to this integration approach, the task shifting principle should be 
implemented for improvement of treatment initiation rates in Kentucky. This 
answers a potential question: who should coordinate the integrated services and 
manage HCV using the DAAs? The primary provider is the most convenient and 
is best positioned to offer the HCV DAAs-based therapy (Pawlotsky, Feld, 
Zeuzem, & Hoofnagle, 2015; Thornton et al., 2016).   
The quantitative results revealed that less than one quarter (22.16%) of 
the patients in this study cohort initiated treatment during the observation period 
after referral. This proportion is comparable to the estimates for the proportion of 
patients who initiated treatment among those referred to care at the national level 
which ranged from 18.33% to 30% (Holmberg, Spradling, Moorman, & 
Denniston, 2013). However, the Kentucky Clinic initiation rates are lower than 
another national treatment initiation estimate pointing to a percentage between 
those who were prescribed treatment (58.35%) and those who achieved SVR 
(34.30%) out of the total patients with a confirmed HCV RNA test (Yehia, 
Schranz, Umscheid, & Lo Re, 2014). Chhatwal et al. (2016) estimated that the 
2015 the national treatment initiation rate was about 33.34% of those 
theoretically prepared for referral, given their HCV status awareness and 
insurance coverage. This lower estimate is still higher than our study results. 
Moreover, our results are lower than the 2013 VHA results which determined that 
24.5% of the patients linked to care initiated treatment; probably IFN-based 
therapy (Meyer et al., 2015) and was close to the homeless veterans’ initiation 
rate (22.9%) (Noska, Belperio, Loomis, O’Toole, & Backus, 2017). Check hep-C 
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2012-2013 multicenter initiation rates are higher than our results as well (29.8%) 
(Ford et al., 2017).  
Racial groups distribution in this study’s participants reflects the 
predominant Caucasian population in Kentucky. However, only 20.66% of the 
Caucasians initiated treatment compared to 45.45% of the African American 
participants. This result is the inverse of the initiation rate favoring Caucasians in 
other studies (Kanwal et al., 2016; Vutien, Hoang, Brooks, Nguyen, & Nguyen, 
2016).   
Our study results demonstrated a predominance of young HCV patients; 
63.86% of all participants were born after 1965. This finding is higher than the 
New York City Check HepC Program distribution which showed only 55% born 
after 1965 (Ford et al., 2017).  
The insurance coverage distribution of our study participants showed that 
Medicaid had the highest proportion (73.3%), which contrasts with the 2015 
finding that revealed that Medicaid patients who had HCV infection represented 
24% of all insurance types (Chhatwal et al., 2016). Moreover, the initiation rate 
among the current study Medicaid patients is obviously low (14.26%) compared 
to Medicare (49.55%), and private and other types of insurance patients 
(38.52%).  
The distribution of age group, insurance type, and liver disease condition 
characteristics of the whole study cohort showed an obvious discrepancy from 
the characteristics of the patients who initiated treatment. The youngest group of 
patients, born after 1965, comprised almost two thirds of the whole cohort but 
only one third of those who initiated treatment. The Medicaid patients who 
comprised three quarters of the cohort represented less than half of the patients 
who initiated treatment. Similar to the age group pattern, mild liver disease 
patients represented two third of the whole cohort, but less than one third of the 
treatment initiation patients.  
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Consistent distribution of the entire cohort and the patients who initiated 
treatment characteristics were found. Higher proportions of treatment initiation 
were found in males, non-Fayette residents, patients with a single genotype of 
HCV, and patients with history of substance abuse.   
Given the high proportion of patients with history of substance abuse 
among the study participants (72.95%), their higher initiation rate does not reflect 
greater privilege for treatment initiation since their proportion compared to their 
group total is only 18.85%, whereas those without a history of substance abuse 
who initiated treatment represented 31.1% of the group total. The same concept 
applies to the patients who reside far from the Kentucky Clinic and reflects the 
predominance of HCV in the Appalachian Mountains in southeast Kentucky.  
Time to treatment initiation results are consistent with the long waiting time 
found in the model of care results. The average time to treatment initiation is 
263.57 days. The cumulative incidence of treatment initiation showed a higher 
rate in the first half of the incidence curve compared to the second half. 
Univariate analysis using Kaplan-Meier time to treatment initiation estimates 
showed significant earlier treatment among males, African Americans, patients 
who followed-up at least once, and patients without a history of substance abuse. 
The disproportionate treatment initiation achievement among the patients born 
before 1965 was inconsistent under Medicaid coverage and with mild liver 
disease; patients showed significantly later treatment initiation at different points 
of time. Bivariate analysis of insurance and liver disease condition showed that 
Medicaid patients with mild liver disease had the lowest chance for treatment 
initiation at different time points compared to other groups.  
The cox model significance results confirmed the previous results on age 
group, insurance type, and liver disease condition. Medicare baby boomers have 
almost double and more than quadruple the likelihood of Medicaid baby boomers 
to initiate treatment at advanced and mild liver disease stages respectively. This 
likelihood jumps to five and thirteen times respectively on comparing patients 
born after 1965 with the same characteristics. Likewise, Medicaid baby boomers 
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have less than half the likelihood of private and other insurance patients to 
initiate treatment at either disease stages. In parallel, the Medicaid patients born 
after 1965 have nearly quarter the likelihood of private and other insurance 
patients to initiate treatment at either disease stage. The only significant 
likelihood difference between Medicare and private and other types of insurance 
was found among mild liver disease patients born after 1965 where the former 
group are three times as likely as the latter group to initiate treatment.  
II- Conclusion 
This study provides a comprehensive view and analysis of the interrelated 
barriers to the DAAs treatment initiation at the Kentucky Clinic. These barriers do 
not exist neither in isolation from each other nor from their influencing factors. 
The main current model of care obstacles include: lack of proper preparation of 
patients for the DAAs treatment administrative and clinical processes; lack of 
communication between the three facilities: the referring, the scheduling, and the 
HCV treatment facility; including long waiting times and lengthy processes. In 
general, the HCV treatment services are broken and not properly connected with 
other services needed by HCV patients.  
Collectively from the quantitative results, the current profile of the least 
privileged patients reveals that accessing the DAAs treatment is poor among 
patients: on Medicaid, born after 1965, with mild liver disease condition, with a 
history of substance abuse, and those residing in remote areas.  
Accordingly, we reject both null hypotheses since the current model of 
care possess different barriers hindering treatment initiation and the 
characteristics of the patients who initiate treatment are significantly different 
from the patients who do not.    
To this end, addressing the identified barriers is important for readjusting 
the current model of care in order to accommodate the needs of the Kentucky 
Clinic patients. 
106 
 
III- Recommendations 
The study results emphasize the need for collective actions to improve 
access to DAAs treatment in Kentucky. All such efforts must be situated within a 
patient centered comprehensive model of care (figure 17). 
The cornerstone for effective linkage to care is a well-established patient 
navigation system. This proposed system should engage the patients at the 
earliest stage of the disease and where he/she lives. Screening and linkage to 
care should be active rather than the most common accidental discovery. Using 
mobile clinics to access difficult to reach populations with a high HCV prevalence 
rate in the Appalachian Mountains could provide a solution for linking 
geographically disadvantaged patients to the standardized DAAs treatment. 
However, the expected driven demand should be met by a responsive and well 
prepared supply side.  
A fundamental point is that the navigation system works by improving 
linkage and continuity of care in a comprehensive manner. The patient navigator 
could be a social worker, community health worker, or a counseling psychologist 
based on the patient’s geographical, cultural, and behavioral needs. The 
navigation should commence with a patient needs assessment to ensure 
success. The role of the patient navigator is crucial in providing necessary 
education to patients about the disease and the treatment processes. In parallel, 
understanding how patients perceive the value and procedures of HCV treatment 
is necessary to tailor a Kentucky specific educational curriculum for the patients. 
In addition, these navigators could play an important role in increasing 
awareness among the referral facilities about the administrative and clinical 
procedures required for the DAAs treatment approval. Training health services 
providers at all possible points for the discovery of HCV with special focus on the 
referring providers in Kentucky should be the ultimate goal.
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Figure 17. Proposed patient centered comprehensive model of care to improve access to hepatitis C virus 
directly acting antivirals treatment in the Kentucky Clinic 
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There is potential to build an integrated healthcare model centered on the 
patient’s needs. Basically, this model should include all services required by the 
patient; e.g., primary care and substance abuse services. The starting point 
should be the most convenient and the natural access point for the patients. The 
multidisciplinary team engaged in initiating treatment should act together; 
however, the primary provider is positioned best to carry out the coordinating 
role. Moreover, the primary care services in an ideal model to provide HCV 
treatment by applying the task shifting approach. Finally, social services; e.g., 
housing and transportation, could be woven into the integrated model to ensure 
success. 
Administrative support for the HCV clinic at the Kentucky Clinic should 
employ a data linkage information system with other facilities to ensure continuity 
of care and to speed up the treatment initiation process. Special support for the 
PA process can be provided by pharmacy students to speed it up and help 
improve the PA approval rates.  
HCV treatment services should prioritize the least privileged patients to 
initiate treatment. Allocation of resources and efforts should focus on: young 
HCV patients living in Kentucky’s southeastern Appalachian Mountains, Medicaid 
patients, patients with mild liver disease, and those involved in substance abuse. 
Finally, investment in patient centered applied research to identify other 
barriers not covered in this study, with special consideration to the patients’ 
acceptance and geographical access dimensions is important. The overall 
picture can help fill in pieces that are arguably missing in the study results.  
IV- Summary 
HCV chronic infection is a major public health problem in Kentucky with 
particular relevance to the drug abuse epidemic in the Appalachian Mountains.  
In parallel, there is an unprecedented advancement in the history of HCV 
control with the availability of highly effective DAAs. On condition that an effective 
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access to the DAAs can be reached, HCV infection is almost a curable disease. 
Additionally, the curative solution offered by the DAAs for HCV chronic infection 
is a real benefit to the public’s health by preventing further infections and 
reducing the risk of the negative health and economic outcomes from liver 
disease. DAAs treatment initiation is not only a major public health problem in 
Kentucky, but also a health equity and social justice issue. 
However, access to treatment in the Kentucky Clinic is hindered by a 
variety of barriers revolving mainly around the model of care, which is greatly 
influenced by the insurance system. In addition, chronic HCV is strongly 
stigmatized by both the society and the healthcare system. This stigma is 
reflected in the restrictive PA requirements particularly for the patients who are 
involved in injection drug use.  
In conclusion, access to DAAs’ treatment initiation is too complex to be 
solved by reducing their prices alone; structural adjustment for the model of care 
and prioritizing the disproportionately affected groups of patients by HCV 
infection is needed as well. Therefore, timely treatment with DAAs addressing the 
current model of care barriers and patients’ characteristics based restrictions 
should be a priority to improve the public’s health in Kentucky. This study makes 
suggestions to improve access to HCV treatment initiation by proposing a patient 
centered comprehensive model of care. 
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